BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. [PMID: 19704057 DOI: 10.1200/jco.2009.22.8510] [Cited by in Crossref: 1609] [Cited by in F6Publishing: 1759] [Article Influence: 114.9] [Reference Citation Analysis]
Number Citing Articles
1 Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, Tarsitano MG, Isidori AM, Colao A, Faggiano A; NIKE Group. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J Endocrinol Invest 2023;46:213-34. [PMID: 36038743 DOI: 10.1007/s40618-022-01905-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Clement DSVM, Leerdam MEV, de Jong S, Weickert MO, Ramage JK, Tesselaar MET, Srirajaskanthan R. Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours. Cancers 2023;15:782. [DOI: 10.3390/cancers15030782] [Reference Citation Analysis]
3 Liu M, Wei L, Liu W, Chen S, Guan M, Zhang Y, Guo Z, Liu R, Xie P. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1079575] [Reference Citation Analysis]
4 Ramesh A, Chatterjee A, Subramaniam RM. Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management. PET Clin 2023:S1556-8598(22)00076-1. [PMID: 36707369 DOI: 10.1016/j.cpet.2022.10.002] [Reference Citation Analysis]
5 Wang Z, Liu F, Li C, Yuan H, Xiang Y, Wei C, Zhu D, Wang M. Case Report: Octreotide plus CVD chemotherapy for the treatment of multiple metastatic paragangliomas after double resection for functional bladder paraganglioma and urothelial papilloma. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1072361] [Reference Citation Analysis]
6 Angelousi A, Koumarianou A, Chatzellis E, Kaltsas G. Resistance of neuroendocrine tumours to somatostatin analogs. Expert Rev Endocrinol Metab 2023;:1-20. [PMID: 36651768 DOI: 10.1080/17446651.2023.2166488] [Reference Citation Analysis]
7 Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D, Brizzi MP, Lamberti G, La Salvia A. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. J Clin Med 2023;12. [PMID: 36675645 DOI: 10.3390/jcm12020717] [Reference Citation Analysis]
8 Kurita Y, Kobayashi N, Hara K, Mizuno N, Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Sato T, Hosono K, Kato S, Kessoku T, Endo I, Shimizu Y, Kubota K, Nakajima A, Ichikawa Y, Niwa Y. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Intern Med 2023;62:159-67. [PMID: 35705270 DOI: 10.2169/internalmedicine.9416-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Frilling A, Clift A. Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_52] [Reference Citation Analysis]
10 Kirschbaum A. Neuroendokrine Neoplasien des Thymus. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_50] [Reference Citation Analysis]
11 Minczeles NS, de Herder WW, Feelders RA, Verburg FA, Hofland J, Brabander T. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients. J Nucl Med 2023;64:40-6. [PMID: 35680417 DOI: 10.2967/jnumed.122.263856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Marcal LP, Chuang HH, Tran Cao HS, Halperin DM. Pancreatic Neuroendocrine Tumors. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00014-8] [Reference Citation Analysis]
13 Chen L, Jumai N, He Q, Liu M, Lin Y, Luo Y, Wang Y, Chen MH, Zeng Z, Zhang X, Zhang N. The role of quantitative tumor burden based on [(68) Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imaging 2023;50:525-34. [PMID: 36181533 DOI: 10.1007/s00259-022-05971-x] [Reference Citation Analysis]
14 Russo A, Gangi A. The Evolving Landscape of Neuroendocrine Tumors. Surg Oncol Clin N Am 2023;32:185-98. [PMID: 36410917 DOI: 10.1016/j.soc.2022.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mohamed A, Wu S, Hamid M, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Asa SL. Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines. Cancers (Basel) 2022;15. [PMID: 36612291 DOI: 10.3390/cancers15010295] [Reference Citation Analysis]
16 Li Y, Hua R, He J, Zhang H. Clinicopathological Features and Prognosis Analysis of Primary Bile Duct and Ampullary Neuroendocrine Neoplasms: A Population-Based Study from 1975 to 2016. Curr Oncol 2022;30:449-61. [PMID: 36661685 DOI: 10.3390/curroncol30010036] [Reference Citation Analysis]
17 Park H, Subramaniam RM. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy. PET Clin 2022:S1556-8598(22)00092-X. [PMID: 36585338 DOI: 10.1016/j.cpet.2022.11.005] [Reference Citation Analysis]
18 Koehler K, Iams WT. Carcinoid tumors outside the abdomen. Cancer Med 2022. [PMID: 36560885 DOI: 10.1002/cam4.5564] [Reference Citation Analysis]
19 Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, Mazzuca F, Tomao S. Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. Cancer Manag Res 2022;14:3507-23. [PMID: 36575665 DOI: 10.2147/CMAR.S372776] [Reference Citation Analysis]
20 Fujimoto K, Koyama F, Kuge H, Obara S, Iwasa Y, Takei T, Takagi T, Sadamitsu T, Harada S, Uchiyama T, Ohbayashi C, Nishiofuku H, Tanaka T, Sho M. Liver metastases of a neuroendocrine tumor arising from a tailgut cyst treated with interventional locoregional therapies: a case report and review of the literature on recurrent cases. Int Canc Conf J 2022. [DOI: 10.1007/s13691-022-00587-2] [Reference Citation Analysis]
21 Shi C, Morse MA. Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2022;14. [PMID: 36551599 DOI: 10.3390/cancers14246114] [Reference Citation Analysis]
22 Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne) 2022;9:1034315. [PMID: 36569154 DOI: 10.3389/fmed.2022.1034315] [Reference Citation Analysis]
23 Viol F, Sipos B, Fahl M, Clauditz TS, Amin T, Kriegs M, Nieser M, Izbicki JR, Huber S, Lohse AW, Schrader J. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. Cell Oncol (Dordr) 2022. [PMID: 36269546 DOI: 10.1007/s13402-022-00727-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Concors SJ, Maxwell JE. Neuroendocrine hepatic metastatic disease: the surgeon's perspective. Abdom Radiol (NY) 2022;47:4073-80. [PMID: 35476146 DOI: 10.1007/s00261-022-03515-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lenneman C, Harrison D, Davis SL, Kondapalli L. Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities. Curr Treat Options Oncol 2022;23:1793-803. [PMID: 36417147 DOI: 10.1007/s11864-022-01023-6] [Reference Citation Analysis]
26 Chi Y, Song L, Liu W, Zhou Y, Miao Y, Fang W, Tan H, Shi S, Jiang H, Xu J, Jia R, Zheng B, Jiang L, Zhao J, Zhang R, Tan H, Wang Y, Chen Q, Yang M, Guo X, Tong Z, Qi Z, Zhao F, Yan X, Zhao H. S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. eClinicalMedicine 2022;54:101667. [DOI: 10.1016/j.eclinm.2022.101667] [Reference Citation Analysis]
27 Jafari P, Husain AN, Setia N. All Together Now. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.09.012] [Reference Citation Analysis]
28 Evans JS, Beaumont J, Braga M, Masrour N, Mauri F, Beckley A, Butt S, Karali CS, Cawthorne C, Archibald S, Aboagye EO, Sharma R. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. Eur J Cancer 2022;176:110-20. [PMID: 36208569 DOI: 10.1016/j.ejca.2022.09.009] [Reference Citation Analysis]
29 Muttillo EM, Mazzarella G, Picardi B, Rossi S, Cinelli L, Diana M, Baiocchini A, Felli E, Pessaux P, Felli E, Muttillo IA. Treatment strategies for neuroendocrine liver metastases: a systematic review. HPB (Oxford) 2022;24:1832-43. [PMID: 35794053 DOI: 10.1016/j.hpb.2022.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kawasaki K, Rekhtman N, Quintanal-villalonga Á, Rudin CM. Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nat Rev Clin Oncol 2022. [DOI: 10.1038/s41571-022-00696-0] [Reference Citation Analysis]
31 Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D. Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers 2022;14:5248. [DOI: 10.3390/cancers14215248] [Reference Citation Analysis]
32 Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm083.pub2] [Reference Citation Analysis]
33 Hainsworth JD, Greco FA. Neoplasms of Unknown Primary Site. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm124.pub2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mizuno Y, Ito T, Ueda K, Tashiro A, Kubota Y, Yamashita A, Miura M, Hayama H, Oya M, Tsuneyoshi M. A case of erythema multiforme-like rash induced by everolimus in a patient with a pancreatic neuroendocrine tumor. Clin J Gastroenterol 2022. [PMID: 36264476 DOI: 10.1007/s12328-022-01709-2] [Reference Citation Analysis]
35 Yamamoto S, Sakakibara N, Hirano H, Morizane C, Honma Y, Hijioka S, Okusaka T, Higashi T, Kawai A. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. Sci Rep 2022;12:17601. [PMID: 36266484 DOI: 10.1038/s41598-022-22718-8] [Reference Citation Analysis]
36 Panzuto F, Ricci C, Rinzivillo M, Magi L, Marasco M, Lamberti G, Casadei R, Campana D. The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. JCM 2022;11:6127. [DOI: 10.3390/jcm11206127] [Reference Citation Analysis]
37 Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors. Cancer Manag Res 2022;14:3009-20. [PMID: 36262750 DOI: 10.2147/CMAR.S386419] [Reference Citation Analysis]
38 Castle JT, Levy BE, Chauhan A. Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability. Cancers (Basel) 2022;14:5049. [PMID: 36291833 DOI: 10.3390/cancers14205049] [Reference Citation Analysis]
39 Wu Z, Qiu X, Zhi Y, Shi X, Lv G. The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database. Front Oncol 2022;12:993524. [DOI: 10.3389/fonc.2022.993524] [Reference Citation Analysis]
40 Laschinsky C, Herrmann K, Fendler W, Nader M, Lahner H, Hadaschik B, Sandach P. Onkologische Theranostik in der Nuklearmedizin. Radiologie 2022;62:875-884. [DOI: 10.1007/s00117-022-01072-w] [Reference Citation Analysis]
41 Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2022:S0889-8588(22)00073-9. [PMID: 36154786 DOI: 10.1016/j.hoc.2022.07.005] [Reference Citation Analysis]
42 Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther 2022. [PMID: 36136274 DOI: 10.1007/s40487-022-00208-1] [Reference Citation Analysis]
43 Pozas J, Alonso-Gordoa T, Román MS, Santoni M, Thirlwell C, Grande E, Molina-Cerrillo J. Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. Biochim Biophys Acta Rev Cancer 2022;1877:188804. [PMID: 36152904 DOI: 10.1016/j.bbcan.2022.188804] [Reference Citation Analysis]
44 Ryzhkova D, Mitrofanova L, Tsoy U, Grineva E, Schlyakhto E. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review. Front Endocrinol 2022;13:958442. [DOI: 10.3389/fendo.2022.958442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Gubbi S, Vijayvergia N, Yu JQ, Klubo-Gwiezdzinska J, Koch CA. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Horm Metab Res 2022;54:795-812. [PMID: 35878617 DOI: 10.1055/a-1908-7790] [Reference Citation Analysis]
46 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY) 2022;47:3078-100. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
47 Raj N, Cruz E, O'shaughnessy S, Calderon C, Chou JF, Capanu M, Heffernan O, Demore A, Punn S, Le T, Hauser H, Saltz L, Reidy-lagunes D. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncology Practice 2022;18:e1533-e1541. [DOI: 10.1200/op.22.00055] [Reference Citation Analysis]
48 Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C. Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data. Neurosurg Rev 2022. [PMID: 35984552 DOI: 10.1007/s10143-022-01849-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 2022;27:940-51. [PMID: 35983951 DOI: 10.1093/oncolo/oyac161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of Radioembolization in Metastatic Neuroendocrine Tumors. Cardiovasc Intervent Radiol 2022. [PMID: 35918431 DOI: 10.1007/s00270-022-03206-y] [Reference Citation Analysis]
51 Wheless M, Das S. Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.08.003] [Reference Citation Analysis]
52 Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022;23:493-9. [PMID: 36081250 DOI: 10.1111/1751-2980.13123] [Reference Citation Analysis]
53 Sharma R, Slater S, Evans J, Martinez M, Ward C, Izadi H, Wernig F, Thomas R. ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs). BMC Cancer 2022;22:800. [PMID: 35858849 DOI: 10.1186/s12885-022-09859-9] [Reference Citation Analysis]
54 Tartaglia A, Busonero G, Gagliardi L, Boddi V, Pieri F, Nizzoli M. Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review. Discov Oncol 2022;13:66. [PMID: 35838801 DOI: 10.1007/s12672-022-00531-z] [Reference Citation Analysis]
55 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
56 Howe JR. Sequencing of Therapies in Progressive Neuroendocrine Tumors. Ann Surg Oncol 2022. [PMID: 35816247 DOI: 10.1245/s10434-022-12149-0] [Reference Citation Analysis]
57 Torbenson M, Venkatesh SK, Halfdanarson TR, Navin PJ, Kamath P, Erickson LA. Primary Neuroendocrine Tumors and Primary Neuroendocrine Carcinomas of the Liver: A Proposal for a Multidiscipline Definition. Hum Pathol 2022:S0046-8177(22)00174-5. [PMID: 35809684 DOI: 10.1016/j.humpath.2022.07.001] [Reference Citation Analysis]
58 Laschinsky C, Herrmann K, Fendler W, Nader M, Lahner H, Hadaschik B, Sandach P. Onkologische Theranostik in der Nuklearmedizin. Onkologie 2022;28:612-622. [DOI: 10.1007/s00761-022-01164-1] [Reference Citation Analysis]
59 Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen HJ, Geboes K, de Herder WW, Munir A. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. Eur J Cancer Care (Engl) 2022;:e13639. [PMID: 35735226 DOI: 10.1111/ecc.13639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Staal FC, Taghavi M, Hong EK, Tissier R, van Treijen M, Heeres BC, van der Zee D, Tesselaar ME, Beets-Tan RG, Maas M. CT-based radiomics to distinguish progressive from stable neuroendocrine liver metastases treated with somatostatin analogues: an explorative study. Acta Radiol 2022;:2841851221106598. [PMID: 35702011 DOI: 10.1177/02841851221106598] [Reference Citation Analysis]
61 Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol 2022;:e13174. [PMID: 35794780 DOI: 10.1111/jne.13174] [Reference Citation Analysis]
62 Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2022;12:901435. [DOI: 10.3389/fonc.2022.901435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Iravani A, Parihar AS, Akhurst T, Hicks RJ. Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00465-3] [Reference Citation Analysis]
64 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Hartrampf P, Werner R, Buck A. Theranostics bei gut bis mäßig differenzierten GEP-NEN. Zentralbl Chir 2022;147:249-255. [DOI: 10.1055/a-1826-3423] [Reference Citation Analysis]
66 Mandriani B, Pellè E, Mannavola F, Palazzo A, Marsano RM, Ingravallo G, Cazzato G, Ramello MC, Porta C, Strosberg J, Abate-Daga D, Cives M. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. J Immunother Cancer 2022;10:e004854. [PMID: 35764366 DOI: 10.1136/jitc-2022-004854] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [DOI: 10.3748/wjg.v28.i20.2163] [Reference Citation Analysis]
68 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
69 Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Metastatic pheochromocytomas and paragangliomas: where are we? Tumori 2022;:3008916221078621. [PMID: 35593402 DOI: 10.1177/03008916221078621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. Cancers (Basel) 2022;14:2514. [PMID: 35626118 DOI: 10.3390/cancers14102514] [Reference Citation Analysis]
71 Kostiainen I, Karppinen N, Simonen P, Rosengård-Bärlund M, Lindén R, Tarkkanen M, Gordin D, Rapola J, Schalin-Jäntti C, Matikainen N. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours. Endocrine 2022. [PMID: 35536452 DOI: 10.1007/s12020-022-03065-0] [Reference Citation Analysis]
72 Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767 [DOI: 10.3748/wjg.v28.i17.1751] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kiesewetter B, Mazal P, Kretschmer-Chott E, Mayerhoefer ME, Raderer M. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open 2022;7:100478. [PMID: 35525183 DOI: 10.1016/j.esmoop.2022.100478] [Reference Citation Analysis]
74 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Jiang H, Zhang H. Clinical and Pathological Features of Primary Renal Well-Differentiated Neuroendocrine Tumor. OTT 2022;Volume 15:587-96. [DOI: 10.2147/ott.s364545] [Reference Citation Analysis]
76 Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
77 Koch C, Bambey C, Filmann N, Stanke M, Waidmann O, Husmann G, Bojunga J. Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors. J Clin Med 2022;11:2358. [PMID: 35566487 DOI: 10.3390/jcm11092358] [Reference Citation Analysis]
78 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Krieg S, Roderburg C, Fung S, Luedde T, Knoefel WT, Krieg A. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04013-1] [Reference Citation Analysis]
80 Hernandez‐barco YG, Chung DC. Neuroendocrine tumors of the pancreas. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch80] [Reference Citation Analysis]
81 Cox T, O'Connell M, Leeuwenkamp O, Palimaka S, Reed N. Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. Curr Med Res Opin 2022;:1-33. [PMID: 35418254 DOI: 10.1080/03007995.2022.2065146] [Reference Citation Analysis]
82 Komoto I, Kokudo N, Aoki T, Morizane C, Ito T, Hashimoto T, Kimura W, Inoue N, Hasegawa K, Kondo S, Ueno H, Igarashi H, Oono T, Makuuchi M, Takamoto T, Hirai I, Takeshita A, Imamura M. Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Jpn J Clin Oncol 2022:hyac048. [PMID: 35411926 DOI: 10.1093/jjco/hyac048] [Reference Citation Analysis]
83 Muñoz de Nova JL, Hernando J, Sampedro Núñez M, Vázquez Benítez GT, Triviño Ibáñez EM, del Olmo García MI, Barriuso J, Capdevila J, Martín-Pérez E. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy. World J Gastroenterol 2022; 28(13): 1304-1314 [DOI: 10.3748/wjg.v28.i13.1304] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Zheng-Pywell R, Lopez-Aguiar A, Fields RC, Vickers S, Yates C, Dudeja V, Chen H, Reddy S, Maithel SK, Rose JB. Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. J Am Coll Surg 2022;234:599-606. [PMID: 35380181 DOI: 10.1097/XCS.0000000000000105] [Reference Citation Analysis]
85 Crook C, Zhang YH, Li D. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs Aging 2022;39:257-69. [PMID: 35332446 DOI: 10.1007/s40266-022-00934-1] [Reference Citation Analysis]
86 Harrow B, Fagnani F, Nevoret C, Truong-Thanh XM, de Zélicourt M, de Mestier L. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting. Adv Ther 2022;39:1754-71. [PMID: 35190997 DOI: 10.1007/s12325-022-02060-1] [Reference Citation Analysis]
87 Mehl L, Schrader J, Winterberg T, Daniels T, Gross A, Weidner U, Clauditz TS, Lock G. Ungewöhnliche Ursache einer Hyperkalzämie in der Schwangerschaft. TumorDiagnostik & Therapie 2022;43:181-186. [DOI: 10.1055/a-1744-2925] [Reference Citation Analysis]
88 Perez K, Chan J. Medical management of gastrointestinal neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes 2022;29:219-24. [PMID: 35045527 DOI: 10.1097/MED.0000000000000711] [Reference Citation Analysis]
89 Vayzband V, Doukas S, Esparragoza P. Esophageal Neuroendocrine Carcinoma: Case Report and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.23607] [Reference Citation Analysis]
90 Liu Y, Liu H, Chen W, Yu H, Yao W, Fan W, Li J, Chen M, Chen J, Wang Y. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. Cancer Med 2022. [PMID: 35289113 DOI: 10.1002/cam4.4628] [Reference Citation Analysis]
91 Gosain R, Gupta M, Roy AM, Strosberg J, Glaser KM, Iyer R. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers 2022;14:1428. [DOI: 10.3390/cancers14061428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Rizen EN, Phan AT. Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep 2022. [PMID: 35254612 DOI: 10.1007/s11912-022-01217-z] [Reference Citation Analysis]
93 Mejia A, Vivian E, Nwogu C, Shah J, Longoria R, Vo A, Shahin I, Verma J, Bageac A. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting. Medicine (Baltimore) 2022;101:e28970. [PMID: 35244064 DOI: 10.1097/MD.0000000000028970] [Reference Citation Analysis]
94 Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front Endocrinol (Lausanne) 2021;12:793262. [PMID: 35058882 DOI: 10.3389/fendo.2021.793262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Ishida H, Lam AK. Pancreatic Neuroendocrine Neoplasms: Updates on Genomic Changes in Inherited Tumour Syndromes and Sporadic Tumours Based on WHO Classification. Crit Rev Oncol Hematol 2022;:103648. [PMID: 35248713 DOI: 10.1016/j.critrevonc.2022.103648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
96 Lee S, Maegawa FB, Joseph S, Alvarado LA, Mendoza-Ladd A, Elhanafi S, Philipovskiy A, Tyroch AH, Konstantinidis IT. Pancreatic Neuroendocrine Tumors: The Effect of Facility Type on Patient Survival. Pancreas 2022;51:282-7. [PMID: 35584387 DOI: 10.1097/MPA.0000000000002014] [Reference Citation Analysis]
97 Mahmoud AS, Abu Bakar MZ, Hamzah H, Tengkue Ahmad TA, Mohd Noor MH. Octreotide acetate enhanced radio sensitivity and induced apoptosis in MCF7 breast cancer cell line. Journal of Radiation Research and Applied Sciences 2022;15:193-8. [DOI: 10.1016/j.jrras.2022.01.008] [Reference Citation Analysis]
98 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
99 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
100 van Leeuwaarde RS, González-Clavijo AM, Pracht M, Emelianova G, Cheung WY, Thirlwell C, Öberg K, Spada F. A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. J Clin Med 2022;11:1271. [PMID: 35268362 DOI: 10.3390/jcm11051271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Koessler T, Alsina M, Arnold D, Ben-Aharon I, Collienne M, Lutz MP, Neuzillet C, Obermannova R, Peeters M, Sclafani F, Smyth E, Valle JW, Wagner AD, Wyrwicz L, Fontana E, Moehler M. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO Open 2022;7:100392. [PMID: 35180656 DOI: 10.1016/j.esmoop.2022.100392] [Reference Citation Analysis]
102 Sharma S, Kapoor VK. Gastrointestinal Neuroendocrine Neoplasms. Indian Journal of Endocrine Surgery and Research 2022;16:51-58. [DOI: 10.5005/jp-journals-10088-11177] [Reference Citation Analysis]
103 Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregni E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2022;5:e220290. [PMID: 35201309 DOI: 10.1001/jamanetworkopen.2022.0290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
104 Patel KR, Nahar A, Elhassan YS, Shetty S, Smith S, Vickrage S, Kemp‐blake J, Palani R, Geh I, Venkataraman H, Shah T, Ayuk J. The effects of somatostatin analogues on glycaemia in the treatment of neuroendocrine tumours. J Neuroendocrinology. [DOI: 10.1111/jne.13064] [Reference Citation Analysis]
105 Bolanowski M, Kałużny M, Witek P, Jawiarczyk-Przybyłowska A. Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord 2022. [PMID: 35067849 DOI: 10.1007/s11154-022-09710-3] [Reference Citation Analysis]
106 Ando T, Sakumura M, Mihara H, Fujinami H, Yasuda I. A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare 2022;10:218. [DOI: 10.3390/healthcare10020218] [Reference Citation Analysis]
107 Araujo-Castro M, Pascual-Corrales E, Molina-Cerrillo J, Moreno Mata N, Alonso-Gordoa T. Bronchial Carcinoids: From Molecular Background to Treatment Approach. Cancers (Basel) 2022;14:520. [PMID: 35158788 DOI: 10.3390/cancers14030520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
108 Vemuri KR, Balcerek MI, Mcgowan TE, Love A, Chapman PR. VIPoma: an unsuspecting culprit of severe secretory diarrhoea in a human immunodeficiency virus‐infected patient. Internal Medicine Journal 2022;52:125-9. [DOI: 10.1111/imj.15655] [Reference Citation Analysis]
109 Havasi A, Sur D, Cainap SS, Lungulescu CV, Gavrilas LI, Cainap C, Vlad C, Balacescu O. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers. Int J Mol Sci 2022;23:1109. [PMID: 35163032 DOI: 10.3390/ijms23031109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Evdokimova EV, Artamonova EV, Delectorskaya VV, Chemeris GY, Emelyanova GS, Bagrova SG, Markovich AA. Treatment tactics of new NET G3 subgroup in first line of therapy. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2021-37-20-24] [Reference Citation Analysis]
111 Melhorn P, Kretschmer-chott E, Wolff L, Haug A, Mazal P, Raderer M, Kiesewetter B. Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Ther Adv Med Oncol 2022;14:175883592211383. [DOI: 10.1177/17588359221138389] [Reference Citation Analysis]
112 Nagel I, Herrmann K, Lahner H, Rischpler C, Weber F. Combined medical therapy, nuclear medicine therapy and other therapies in metastatic neuroendocrine tumor. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00156-3] [Reference Citation Analysis]
113 . Endokrines System und Immunmodulation. Arzneimitteltherapie in der Palliativmedizin 2022. [DOI: 10.1016/b978-3-437-23673-0.00008-2] [Reference Citation Analysis]
114 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_50-3] [Reference Citation Analysis]
115 Forrer F. Side effects of radiopeptide therapy for neuroendocrine tumors. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00157-5] [Reference Citation Analysis]
116 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_50-2] [Reference Citation Analysis]
117 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_50] [Reference Citation Analysis]
118 Kabasakal L, Demirci E, Selçuk NA. Radionuclide Therapy in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_9] [Reference Citation Analysis]
119 Valente M, Covre A, Giacomo AMD, Maio M. Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_50] [Reference Citation Analysis]
120 Fottner C, Musholt TJ, Weber MM. Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN). Therapie-Handbuch - Onkologie und Hämatologie 2022. [DOI: 10.1016/b978-3-437-23824-6.00052-3] [Reference Citation Analysis]
121 Alavi K, Boutros M. Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, and Lymphoma. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Foti RS. ADME of Biologicals and New Therapeutic Modalities. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00141-9] [Reference Citation Analysis]
123 Kazaz SN, Öztop İ. Systemic Treatments and Related Side Effects in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_10] [Reference Citation Analysis]
124 Chouthai A, Makar M, Sarkar A. Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_39] [Reference Citation Analysis]
125 Gonzalez C, Desantis A, Read M, Karachristos A. Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_40] [Reference Citation Analysis]
126 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
127 Spada F, Campana D, Lamberti G, Laudicella R, Dellamano R, Dellamano L, Leeuwenkamp O, Baldari S. [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. Eur J Nucl Med Mol Imaging 2021. [PMID: 34950969 DOI: 10.1007/s00259-021-05656-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
128 Sharma N, Sharma D. An Overview of Pancreatic Neuroendocrine Tumors. Challenges in Pancreatic Cancer 2021. [DOI: 10.5772/intechopen.96259] [Reference Citation Analysis]
129 Caplin ME. Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? EJC Suppl 2021;16:1-4. [PMID: 34912477 DOI: 10.1016/j.ejcsup.2021.06.001] [Reference Citation Analysis]
130 Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, O'Dorisio T, O'Dorisio MS, Wild D, Christ E, Nicolas GP. Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. Cancers (Basel) 2021;13:6290. [PMID: 34944910 DOI: 10.3390/cancers13246290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci 2021. [PMID: 34907652 DOI: 10.1002/jhbp.1101] [Reference Citation Analysis]
132 Maurer E, Heinzel-Gutenbrunner M, Rinke A, Rütz J, Holzer K, Figiel J, Luster M, Bartsch DK. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. J Neuroendocrinol 2021;:e13076. [PMID: 34964186 DOI: 10.1111/jne.13076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 de Ponthaud C, Menegaux F, Gaujoux S. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know. Cancers (Basel) 2021;13:5969. [PMID: 34885079 DOI: 10.3390/cancers13235969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Walter MA, Nesti C, Spanjol M, Kollár A, Bütikofer L, Gloy VL, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Kaderli RM. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database Syst Rev 2021;11:CD013700. [PMID: 34822169 DOI: 10.1002/14651858.CD013700.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
136 Sowa-staszczak A, Opalińska M, Kurzyńska A, Morawiec-sławek K, Gilis-januszewska A, Palen-tytko J, Olearska H, Hubalewska-dydejczyk A. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? Medicina 2021;57:1287. [DOI: 10.3390/medicina57121287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:1752-63. [PMID: 34793718 DOI: 10.1016/S1470-2045(21)00572-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
139 Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel) 2021;13:5735. [PMID: 34830886 DOI: 10.3390/cancers13225735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
140 Tawfik B, Ray D, Moynihan M, Princic N. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. J Med Econ 2021;24:1337-45. [PMID: 34763589 DOI: 10.1080/13696998.2021.2005374] [Reference Citation Analysis]
141 Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kröcher A, Kreutzfeldt S, Gress TM, Rinke A. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. Front Endocrinol (Lausanne) 2021;12:709256. [PMID: 34690926 DOI: 10.3389/fendo.2021.709256] [Reference Citation Analysis]
142 Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol 2021; 12(10): 897-911 [PMID: 34733612 DOI: 10.5306/wjco.v12.i10.897] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
144 La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, Faggiano A. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel) 2021;14:1039. [PMID: 34681263 DOI: 10.3390/ph14101039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
146 Carpizo DR, Harris CR. Genetic Drivers of Ileal Neuroendocrine Tumors. Cancers (Basel) 2021;13:5070. [PMID: 34680217 DOI: 10.3390/cancers13205070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Riss P, Scheuba K, Strobel O. [Endocrine and neuroendocrine tumors]. Chirurg 2021;92:996-1002. [PMID: 34618164 DOI: 10.1007/s00104-021-01512-8] [Reference Citation Analysis]
148 Koh TT, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. World J Nucl Med 2021;20:329-35. [PMID: 35018146 DOI: 10.4103/wjnm.wjnm_160_20] [Reference Citation Analysis]
149 Krug S, Michl P. Systemische Therapien neuroendokriner Tumoren und Karzinome. Im Fokus Onkologie 2021;24:28-31. [DOI: 10.1007/s15015-021-3621-1] [Reference Citation Analysis]
150 Sesti F, La Salvia A, Grinzato C, Mazzilli R, Faggiano A. L’approccio con analoghi della somatostatina nelle neoplasie neuroendocrine associate a sindromi neoplastiche multi-endocrine ereditarie. L'Endocrinologo 2021;22:423-428. [DOI: 10.1007/s40619-021-00952-y] [Reference Citation Analysis]
151 Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol 2021;56:1033-44. [PMID: 34586495 DOI: 10.1007/s00535-021-01827-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
152 Klomp MJ, Dalm SU, van Koetsveld PM, Dogan F, de Jong M, Hofland LJ. Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells. Cancers (Basel) 2021;13:4905. [PMID: 34638389 DOI: 10.3390/cancers13194905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel) 2021;13:4872. [PMID: 34638356 DOI: 10.3390/cancers13194872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, Massironi S. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol 2021; 27(35): 5890-5907 [PMID: 34629807 DOI: 10.3748/wjg.v27.i35.5890] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
155 Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Kaneta T, Utsunomiya D, Hata M, Inoue T, Hosono M, Kinuya S, Ichikawa Y. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med 2021;35:1332-41. [PMID: 34533700 DOI: 10.1007/s12149-021-01674-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
156 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
157 Bostan H, Duger H, Akhanli P, Calapkulu M, Turkmenoglu TT, Erdol AK, Duru SA, Sencar ME, Kizilgul M, Ucan B, Ozbek M, Cakal E. Cushing's syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review. Hormones (Athens) 2021. [PMID: 34478059 DOI: 10.1007/s42000-021-00316-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Ronde EM, Heidsma CM, Eskes AM, Schopman JE, Nieveen van Dijkum EJM. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Eur J Cancer Care (Engl) 2021;30:e13504. [PMID: 34462979 DOI: 10.1111/ecc.13504] [Reference Citation Analysis]
159 Weigold F, Leschber G. Neuroendokrine Tumoren der Lunge. Onkologe 2021;27:900-910. [DOI: 10.1007/s00761-021-00966-z] [Reference Citation Analysis]
160 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
161 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PG, Warner SG, Melstrom LG, Kessler J, Fong Y, Li D, Singh G. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Am J Surg 2021:S0002-9610(21)00513-4. [PMID: 34474917 DOI: 10.1016/j.amjsurg.2021.08.030] [Reference Citation Analysis]
162 Atkinson C, Ganeshan B, Endozo R, Wan S, Aldridge MD, Groves AM, Bomanji JB, Gaze MN. Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With 177Lu-DOTATATE. Front Oncol 2021;11:686235. [PMID: 34408979 DOI: 10.3389/fonc.2021.686235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
163 Sharma R, Lythgoe MP, Slaich B, Patel N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers (Basel) 2021;13:4181. [PMID: 34439335 DOI: 10.3390/cancers13164181] [Reference Citation Analysis]
164 O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
165 Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
166 Spyroglou A, Bramis K, Alexandraki KI. Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research 2021;19:15-21. [DOI: 10.1016/j.coemr.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Kjaer J, Stålberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021;5:zrab062. [PMID: 34291287 DOI: 10.1093/bjsopen/zrab062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
168 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
169 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 30.5] [Reference Citation Analysis]
170 Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, Langer SW, Kjaer A, Arola J, Schalin-Jäntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2021;60:931-41. [PMID: 33999752 DOI: 10.1080/0284186X.2021.1921262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
171 Ishikawa R, Kamata K, Hara A, Tanaka H, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Takenaka M, Minami Y, Watanabe T, Chiba Y, Chikugo T, Matsumoto I, Takeyama Y, Matsukubo Y, Hyodo T, Kudo M. Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms. Dig Endosc 2021;33:829-39. [PMID: 33020955 DOI: 10.1111/den.13862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
172 Muffatti F, Partelli S, Andreasi V, Falconi M. Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors. Clinical Pancreatology for Practising Gastroenterologists and Surgeons 2021. [DOI: 10.1002/9781119570097.ch76] [Reference Citation Analysis]
173 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
174 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
175 Guzzardi MA, Pugliese G, Bottiglieri F, Pelosini C, Muscogiuri G, Barrea L, Savastano S, Colao A. Obesity-related gut hormones and cancer: novel insight into the pathophysiology. Int J Obes (Lond) 2021;45:1886-98. [PMID: 34088971 DOI: 10.1038/s41366-021-00865-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
176 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 de Herder WW, Feelders RA, Hofland J. Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;18:139-144. [DOI: 10.1016/j.coemr.2021.03.019] [Reference Citation Analysis]
178 Vaghaiwalla T, Memeh K, Liao C, Keutgen XM. Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and surgical management. Journal of Pancreatology 2021;4:82-9. [DOI: 10.1097/jp9.0000000000000068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Rodrigues M, Svirydenka H, Virgolini I. Theragnostics in Neuroendocrine Tumors. PET Clin 2021;16:365-73. [PMID: 34053580 DOI: 10.1016/j.cpet.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
180 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
182 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 2021;13:17588359211018047. [PMID: 34093744 DOI: 10.1177/17588359211018047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
184 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
185 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
186 Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021;14:476. [PMID: 34067837 DOI: 10.3390/ph14050476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
187 Bando-delaunay A, Vaylet De Labriolle C, Keller-petrot I, Lebtahi R. Résultats et perspectives des traitements par Lutathera des tumeurs neuroendocrines à l’hôpital de Beaujon, centre RENATEN. Médecine Nucléaire 2021;45:119-126. [DOI: 10.1016/j.mednuc.2021.01.005] [Reference Citation Analysis]
188 Baretti M, Zhu Q, Zahurak M, Bhaijee F, Xu H, Engle EL, Kotte A, Pawlik TM, Anders RA, De Jesus-Acosta A. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas 2021;50:719-26. [PMID: 34016898 DOI: 10.1097/MPA.0000000000001831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
189 Aktypis C, Spei ME, Yavropoulou M, Wallin G, Koumarianou A, Kaltsas G, Kassi E, Daskalakis K. Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Cancers (Basel) 2021;13:2159. [PMID: 33946147 DOI: 10.3390/cancers13092159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
190 Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics (Basel) 2021;11:804. [PMID: 33925256 DOI: 10.3390/diagnostics11050804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 Lenotti E, Alberti A, Spada F, Amoroso V, Maisonneuve P, Grisanti S, Baggi A, Bianchi S, Fazio N, Berruti A. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs. Front Endocrinol (Lausanne) 2021;12:669484. [PMID: 33986731 DOI: 10.3389/fendo.2021.669484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
192 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
193 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
194 Hayes AR, Smith K, Liu M, Jenkinson S, Grossman AB, Youle M, Burns F, Thirlwell C, Caplin ME. Treating neuroendocrine neoplasms in the setting of HIV infection. TRD 2021;5:143-159. [DOI: 10.3233/trd-200046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Vida Navas EM, Martínez Lorca A, Sancho Gutiérrez A, Sanz Gómez L, Navarro Martínez T, Grande Pulido E, Carrato Mena A, Gajate Borau P. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:676973. [PMID: 33935979 DOI: 10.3389/fendo.2021.676973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Gillette AA, Babiarz CP, VanDommelen AR, Pasch CA, Clipson L, Matkowskyj KA, Deming DA, Skala MC. Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. Cancers (Basel) 2021;13:1873. [PMID: 33919802 DOI: 10.3390/cancers13081873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
197 Marini F, Giusti F, Tonelli F, Brandi ML. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. Int J Mol Sci 2021;22:4041. [PMID: 33919851 DOI: 10.3390/ijms22084041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
198 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep 2021;11:7881. [PMID: 33846396 DOI: 10.1038/s41598-021-86839-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
199 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
200 La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? Cancers (Basel) 2021;13:1701. [PMID: 33916707 DOI: 10.3390/cancers13071701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
201 Hasegawa S, Kobayashi N, Okubo N, Tokuhisa M, Goto A, Kurita Y, Sato T, Hosono K, Endo I, Nakajima A, Ichikawa Y. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Intern Med 2021;60:977-83. [PMID: 33162477 DOI: 10.2169/internalmedicine.5648-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
202 Cruz Castellanos P, Sánchez Cabrero D, Esteban MI, de Castro J. Estudio retrospectivo descriptivo sobre el tumor carcinoide pulmonar: experiencia de un centro español de tercer nivel. Revista Española de Patología 2021;54:85-91. [DOI: 10.1016/j.patol.2020.04.004] [Reference Citation Analysis]
203 Wang Q, Yu C. Expression profiling of small intestinal neuroendocrine tumors identified pathways and gene networks linked to tumorigenesis and metastasis. Biosci Rep 2020;40:BSR20193860. [PMID: 32496505 DOI: 10.1042/BSR20193860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
204 Aapkes SE, de Haas RJ, Bernts LHP, Blijdorp CJ, Dekker SEI, van Gastel MDA, Meijer E, Veldman A, Drenth JPH, Gansevoort RT; DIPAK consortium. Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation. Drugs R D 2021;21:179-88. [PMID: 33779943 DOI: 10.1007/s40268-021-00342-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Patel M, Tena I, Jha A, Taieb D, Pacak K. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Front Endocrinol (Lausanne) 2021;12:625312. [PMID: 33854479 DOI: 10.3389/fendo.2021.625312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
206 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
207 Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2021. [PMID: 33772332 DOI: 10.1007/s00259-021-05315-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
208 Yazdanpanah O, Surapaneni S, Shanah L, Kabashneh S. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. Cureus 2021;13:e14006. [PMID: 33884247 DOI: 10.7759/cureus.14006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
210 Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27(10): 976-989 [PMID: 33776367 DOI: 10.3748/wjg.v27.i10.976] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology 2021;4:1-17. [DOI: 10.1097/jp9.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Zheng-Pywell R, Fang A, AlKashash A, Awad S, Reddy S, Vickers S, Heslin M, Dudeja V, Chen H, Rose JB. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance. Pancreas 2021;50:347-52. [PMID: 33835965 DOI: 10.1097/MPA.0000000000001776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
213 Tudela-lerma M, Orcajo-rincón J, Ramón-botella E, Álvarez-luque A, Gonzalez-leyte M, Rotger-regi A, Velasco-sánchez E, Colón-rodriguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021;40:82-90. [DOI: 10.1016/j.remnie.2021.01.009] [Reference Citation Analysis]
214 Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:622693. [PMID: 33732215 DOI: 10.3389/fendo.2021.622693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 2021;73:232-9. [PMID: 33544352 DOI: 10.1007/s12020-021-02639-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
216 Cella D, Evans J, Feuilly M, Neggers S, Van Genechten D, Herman J, Khan MS. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Adv Ther 2021;38:969-93. [PMID: 33432541 DOI: 10.1007/s12325-020-01600-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
217 Gatto F. Everolimus e octreotide LAR nel carcinoide differenziato metastatico. L'Endocrinologo 2021;22:77-78. [DOI: 10.1007/s40619-021-00825-4] [Reference Citation Analysis]
218 Sung MJ, Chung MJ. Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor. Korean J Pancreas Biliary Tract 2021;26:24-32. [DOI: 10.15279/kpba.2021.26.1.24] [Reference Citation Analysis]
219 Balakrishna P, George S, Hatoum H, Mukherjee S. Serotonin Pathway in Cancer. Int J Mol Sci 2021;22:1268. [PMID: 33525332 DOI: 10.3390/ijms22031268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
220 Magi L, Rinzivillo M, Panzuto F. Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. Endocrines 2021;2:28-36. [DOI: 10.3390/endocrines2010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab 2021;106:e1937-52. [PMID: 33462603 DOI: 10.1210/clinem/dgaa982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
222 Ricci C, Lamberti G, Ingaldi C, Mosconi C, Pagano N, Alberici L, Ambrosini V, Manuzzi L, Monari F, Malvi D, Rosini F, Minni F, Campana D, Casadei R. Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. Cancers (Basel) 2021;13:358. [PMID: 33561087 DOI: 10.3390/cancers13020358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
223 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
225 Oleinikov K, Korach A, Planer D, Gilon D, Grozinsky-Glasberg S. Update in carcinoid heart disease - the heart of the matter. Rev Endocr Metab Disord 2021;22:553-61. [PMID: 33443717 DOI: 10.1007/s11154-020-09624-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
226 Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers (Basel) 2021;13:E232. [PMID: 33435224 DOI: 10.3390/cancers13020232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
227 Fabian E, Kump P, Schiller D, Brcic I, Gruber C, Heitz PU, Klöppel G, Lipp RW, Moinfar F, Schöfl R, Fickert P, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 173: A 77-year-old patient with adenocarcinoma of the prostate, liver metastases and watery diarrhea. Wien Klin Wochenschr 2021;133:515-22. [PMID: 33398457 DOI: 10.1007/s00508-020-01791-x] [Reference Citation Analysis]
228 Grimaldi F, Vescini F, Kara E. Treatment of NET-Related Symptoms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_7] [Reference Citation Analysis]
229 Limouris GS. Gastro-entero-pancreatic Neuroendocrine Tumors. Liver Intra-arterial PRRT with 111In-Octreotide 2021. [DOI: 10.1007/978-3-030-70773-6_3] [Reference Citation Analysis]
230 Chouthai A, Makar M, Sarkar A. Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_39-1] [Reference Citation Analysis]
231 Fazio N, Spada F, Rossi RE, Ambrosini V, Incorvaia L, Passiglia F, Cani M, Badalamenti G. Neuroendocrine Neoplasms (NENs). Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_60] [Reference Citation Analysis]
232 Kirschbaum A. Neuroendokrine Neoplasien des Thymus. Springer Reference Medizin 2021. [DOI: 10.1007/978-3-662-61724-3_50-1] [Reference Citation Analysis]
233 Leiting JL, Grotz TE. Neuroendocrine Peritoneal Metastases. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_18] [Reference Citation Analysis]
234 Imperiale A, Taïeb D. 18F-FDOPA PET/CT for Treatment Response Assessment. Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology 2021. [DOI: 10.1007/978-3-030-68858-5_28] [Reference Citation Analysis]
235 Bhutiani N, Bruenderman EH, Jones JM, Wehry JH, Egger ME, Philips P, Scoggins CR, McMasters KM, Martin RCG. A literature-based treatment algorithm for low-grade neuroendocrine liver metastases. HPB (Oxford) 2021;23:63-70. [PMID: 32448647 DOI: 10.1016/j.hpb.2020.04.012] [Reference Citation Analysis]
236 Panzuto F, Rinzivillo M. Treatment of Intestinal NETs (Including Appendix). Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_15] [Reference Citation Analysis]
237 Mehtani R, Venkitaraman A, Roy A, Premkumar M. Metastatic Pancreatic Neuroendocrine Tumor With Primary Presentation as Orbital Cellulitis. ACG Case Rep J 2021;8:e00524. [DOI: 10.14309/crj.0000000000000524] [Reference Citation Analysis]
238 Frilling A, Clift A. Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie. Springer Reference Medizin 2021. [DOI: 10.1007/978-3-662-61724-3_52-1] [Reference Citation Analysis]
239 Gupta M, Prinzing G, Iyer R. Emerging Systemic Therapies for Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_20] [Reference Citation Analysis]
240 Valente M, Covre A, Di Giacomo AM, Maio M. Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_50-1] [Reference Citation Analysis]
241 Mirpour S, Ghadimi M, Pawlik TM, Kamel IR. Imaging of Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_2] [Reference Citation Analysis]
242 Prinzi N, Rossi RE, Leuzzi G, Pusceddu S. NETs of the Lung. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_12] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Ramakrishnan N, Ahn SH, Jialal I. Gastroenteropancreatic neuroendocrine tumors. Handbook of Diagnostic Endocrinology 2021. [DOI: 10.1016/b978-0-12-818277-2.00006-6] [Reference Citation Analysis]
244 Betella N, Smiroldo V, Baldelli R, Lania A. Treatment of NETs from Rare Origin. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_16] [Reference Citation Analysis]
245 Goldmann A, Clerici T. Small Intestine NETs. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_29] [Reference Citation Analysis]
246 Gonzalez C, Desantis A, Read M, Karachristos A. Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_40-1] [Reference Citation Analysis]
247 Stechman MJ, Bränström R. Neuroendocrine Tumors (Thymic and Gastroenteropancreatic): Anatomy, Endocrine Physiology, and Pathophysiology. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_24] [Reference Citation Analysis]
248 Chagpar R, Naples R, Siperstein AE. Pancreatic Neuroendocrine Tumors. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00084-0] [Reference Citation Analysis]
249 Carnaghi C, Merola E. Treatment of Pancreatic Neuroendocrine Tumors. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_14] [Reference Citation Analysis]
250 Sherman SK, Howe JR. Jejunoileal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_10] [Reference Citation Analysis]
251 Igaz P. Carcinoid Syndrome Caused by a Small Intestinal Neuroendocrine Tumor. Practical Clinical Endocrinology 2021. [DOI: 10.1007/978-3-030-62011-0_44] [Reference Citation Analysis]
252 Akirov A, Amer L, Chbat J, Ezzat S. The Management of Neuro-Endocrine Neoplasms. The Spectrum of Neuroendocrine Neoplasia 2021. [DOI: 10.1007/978-3-030-54391-4_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
254 Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pellè E, Kolasińska-Ćwikła A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwaarde R. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? Oncologist 2021;26:294-301. [PMID: 33301235 DOI: 10.1002/onco.13633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
255 Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer 2021;144:200-14. [PMID: 33370645 DOI: 10.1016/j.ejca.2020.11.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
256 Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, Reid RH, Laidley DT. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol 2020;28:115-27. [PMID: 33622997 DOI: 10.3390/curroncol28010015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
257 Lehrman ED, Fidelman N. Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy. Semin Intervent Radiol 2020;37:499-507. [PMID: 33328706 DOI: 10.1055/s-0040-1720951] [Reference Citation Analysis]
258 Gao S, Shi X, Ma H, Wang H, Li B, Song B, Guo S, Jin G. The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection. Journal of Pancreatology 2020;3:167-72. [DOI: 10.1097/jp9.0000000000000058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Park R, Chatterjee D, Amin M, Trikalinos NA. Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor. Current Problems in Cancer: Case Reports 2020;2:100037. [DOI: 10.1016/j.cpccr.2020.100037] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Cao Y, Ma Y, Yu J, Sun Y, Sun T, Shao Y, Li J, Shen L, Lu M. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Commun (Lond) 2020;40:746-51. [PMID: 33230973 DOI: 10.1002/cac2.12114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
261 Zanini S, Renzi S, Giovinazzo F, Bermano G. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front Endocrinol (Lausanne). 2020;11:562505. [PMID: 33304317 DOI: 10.3389/fendo.2020.562505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
262 Cives M, Pelle' E, Strosberg J. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. J Clin Med 2020;9:E3655. [PMID: 33202931 DOI: 10.3390/jcm9113655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
263 White BE, Mujica-Mota R, Snowsill T, Gamper EM, Srirajaskanthan R, Ramage JK. Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Rev Endocr Metab Disord 2021;22:647-63. [PMID: 33155118 DOI: 10.1007/s11154-020-09608-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
264 Patel AV, Shah DN, Godbole A, Shah TA, Patel SV. A SYNCHRONOUS INCIDENCE OF ASYMPTOMATIC JEJUNAL GIST IN PATIENT WITH NON- FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR (PNET). ijsr 2020. [DOI: 10.36106/ijsr/2901968] [Reference Citation Analysis]
265 Sharp AJ, Hayes AR, Grossman A. High-dose Somatostatin Analogues for Progressive Neuroendocrine Tumours. Eur Endocrinol 2020;16:93-5. [PMID: 33117438 DOI: 10.17925/EE.2020.16.2.93] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
266 Metz DC, Liu E, Joish VN, Huynh L, Totev TI, Duh MS, Seth K, Giacalone S, Lapuerta P, Morse MA. Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome. Cancer Manag Res 2020;12:9713-9. [PMID: 33116830 DOI: 10.2147/CMAR.S276519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
267 Bober B, Saracyn M, Kołodziej M, Kowalski Ł, Deptuła-Krawczyk E, Kapusta W, Kamiński G, Mozenska O, Bil J. Carcinoid Heart Disease: How to Diagnose and Treat in 2020? Clin Med Insights Cardiol 2020;14:1179546820968101. [PMID: 33192110 DOI: 10.1177/1179546820968101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
268 Bösch F, Altendorf-Hofmann A, Jacob S, Auernhammer CJ, Spitzweg C, Boeck S, Schubert-Fritschle G, Werner J, Kirchner T, Angele MK, Knösel T. Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. J Clin Med 2020;9:E3368. [PMID: 33096620 DOI: 10.3390/jcm9103368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
269 Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22:495-510. [PMID: 33085037 DOI: 10.1007/s11154-020-09607-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
270 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
271 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
272 Leeuwenkamp O, Smith-Palmer J, Ortiz R, Werner A, Valentine W, Blachier M, Walter T. Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. J Med Econ 2020;23:1534-41. [PMID: 32990484 DOI: 10.1080/13696998.2020.1830286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Khan MS, Pritchard DM. Neuroendocrine tumours: what gastroenterologists need to know. Frontline Gastroenterol 2022;13:50-6. [PMID: 34966533 DOI: 10.1136/flgastro-2020-101431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
274 Lee H, Eads JR, Pryma DA. 68 Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors. Oncologist 2021;26:21-9. [PMID: 32886441 DOI: 10.1634/theoncologist.2020-0165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
275 Tsang ES, Loree JM, Speers C, Kennecke HF. Sequence of therapy and survival in patients with advanced pancreatic neuroendocrine tumours. Curr Oncol 2020;27:215-9. [PMID: 32905342 DOI: 10.3747/co.27.5929] [Reference Citation Analysis]
276 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
277 von Arx C, Rea G, Napolitano M, Ottaiano A, Tatangelo F, Izzo F, Petrillo A, Clemente O, Di Sarno A, Botti G, Scala S, Tafuto S. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers (Basel) 2020;12:E2422. [PMID: 32859050 DOI: 10.3390/cancers12092422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
278 Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Duh MS, Seth K, Lapuerta P, Metz DC. Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study. Cancer Manag Res 2020;12:6607-14. [PMID: 32801896 DOI: 10.2147/CMAR.S261257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
279 Gut P. Oncological management of advanced neuroendocrine tumours (Review). Mol Clin Oncol 2020;13:8. [PMID: 32754322 DOI: 10.3892/mco.2020.2078] [Reference Citation Analysis]
280 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
281 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
282 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
283 Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J Gastroenterol 2020; 26(28): 4036-4054 [PMID: 32821069 DOI: 10.3748/wjg.v26.i28.4036] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
284 Trevisi E, La Salvia A, Daniele L, Brizzi MP, De Rosa G, Scagliotti GV, Di Maio M. Neuroendocrine breast carcinoma: a rare but challenging entity. Med Oncol 2020;37:70. [PMID: 32712767 DOI: 10.1007/s12032-020-01396-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
285 Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, Barriuso J, Sergieva S, Gocheva L, Mansoor W, Manoharan P, Valle JW. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers (Basel) 2020;12:E1988. [PMID: 32708210 DOI: 10.3390/cancers12071988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
286 Casey RT, Valk GD, Schalin-Jäntti C, Grossman AB, Thakker RV. ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical management of neuroendocrine neoplasms (NENs). Eur J Endocrinol 2020;183:G79-88. [PMID: 32554825 DOI: 10.1530/EJE-20-0424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
287 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
288 Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
289 Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol 2020;10:1047. [PMID: 32766136 DOI: 10.3389/fonc.2020.01047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
290 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
291 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology 2020;20:875-9. [PMID: 32684368 DOI: 10.1016/j.pan.2020.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
292 Lahner H, Fendler WP, Theurer S, Unger N, Herrmann K, Schmid KW, Führer D. Neuroendokrine Neoplasien des Verdauungstrakts. best practice onkologie 2020;15:320-333. [DOI: 10.1007/s11654-020-00233-4] [Reference Citation Analysis]
293 Akaike T, Qazi J, Anderson A, Behnia FS, Shinohara MM, Akaike G, Hippe DS, Thomas H, Takagishi SR, Lachance K, Park SY, Tarabadkar ES, Iyer JG, Blom A, Parvathaneni U, Vesselle H, Nghiem P, Bhatia S. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. Br J Dermatol 2021;184:319-27. [PMID: 32320473 DOI: 10.1111/bjd.19150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
294 Sorbye H, Meyer LS, Mordal KE, Myhre S, Thiis-Evensen E. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health Qual Life Outcomes 2020;18:188. [PMID: 32546236 DOI: 10.1186/s12955-020-01452-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
295 Palmieri LJ, Dermine S, Barré A, Dhooge M, Brezault C, Cottereau AS, Coriat R. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. J Clin Med 2020;9:E1860. [PMID: 32549203 DOI: 10.3390/jcm9061860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
296 Alvarez M, Almanzar A, Sanabria F, Meneses G, Velasquez L, Zarate L. MANIFESTATIONS OF GLUCAGONOMA SYNDROME. AACE Clin Case Rep 2020;6:e46-9. [PMID: 32524009 DOI: 10.4158/ACCR-2019-0211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
297 Hanif A, Lee S, Gupta M, Chander A, Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood K, Qiu J, Yendamuri S, Iyer R. Exploring the role of survivin in neuroendocrine neoplasms. Oncotarget 2020;11:2246-58. [PMID: 32577168 DOI: 10.18632/oncotarget.27631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
298 Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020;9. [PMID: 32521677 DOI: 10.3390/jcm9061777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
299 Beleù A, Rizzo G, De Robertis R, Drudi A, Aluffi G, Longo C, Sarno A, Cingarlini S, Capelli P, Landoni L, Scarpa A, Bassi C, D'Onofrio M. Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and 18F-FDG Uptake. Cancers (Basel) 2020;12:E1486. [PMID: 32517291 DOI: 10.3390/cancers12061486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
300 Refardt J, Hofland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, Christ E. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord 2021;22:581-94. [PMID: 32495250 DOI: 10.1007/s11154-020-09552-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
301 Pellat A, Coriat R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. J Clin Med. 2020;9. [PMID: 32492939 DOI: 10.3390/jcm9061677] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
302 Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:567-77. [PMID: 32655936 DOI: 10.21037/jgo.2020.03.11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
303 Howe JR. Carcinoid Tumors: Past, Present, and Future. Indian J Surg Oncol 2020;11:182-187. [DOI: 10.1007/s13193-020-01079-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
305 Medaer E, Verslype C, Van Cutsem E, Dekervel J, Clement PM, Nackaerts K, Laenen A, Gheysens O, Goffin K, Jentjens S, Van Laere K, Deroose CM. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT. Acta Oncol 2020;59:644-51. [PMID: 32036716 DOI: 10.1080/0284186X.2020.1723161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
306 Thiis-Evensen E, Poole AC, Nguyen HT, Sponheim J. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. BMC Cancer 2020;20:466. [PMID: 32448245 DOI: 10.1186/s12885-020-06963-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
307 Barrett JR, Abbott DE. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed. J Surg Oncol 2020;122:572. [PMID: 32419171 DOI: 10.1002/jso.25972] [Reference Citation Analysis]
308 Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 2020;12:E1437. [PMID: 32429294 DOI: 10.3390/nu12051437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
309 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
310 Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, Bundschuh RA. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol 2019;21:582-90. [PMID: 30014345 DOI: 10.1007/s11307-018-1252-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
311 Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer 2019;50:816-23. [PMID: 30121904 DOI: 10.1007/s12029-018-0160-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
312 Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020;13:3545-3555. [PMID: 32431509 DOI: 10.2147/ott.s202867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
313 Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, Umutlu L, Herrmann K, Rischpler C. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer 2020;20:326. [PMID: 32299391 DOI: 10.1186/s12885-020-06836-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
314 Adelman D, Truong Thanh XM, Feuilly M, Houchard A, Cella D. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Adv Ther 2020;37:1608-19. [PMID: 32157626 DOI: 10.1007/s12325-020-01255-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
315 Contractor T, Harris CR. Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors. Oncogenesis 2020;9:37. [PMID: 32198354 DOI: 10.1038/s41389-020-0221-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Özdirik B, Kayser A, Ullrich A, Savic LJ, Reiss M, Tacke F, Wiedenmann B, Jann H, Roderburg C. Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. Cancers (Basel) 2020;12:E733. [PMID: 32244940 DOI: 10.3390/cancers12030733] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
317 Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol 2020;121:1067-73. [PMID: 32153032 DOI: 10.1002/jso.25896] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
318 Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G. Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology (Basel) 2020;9:E51. [PMID: 32182791 DOI: 10.3390/biology9030051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging 2020;47:2372-82. [PMID: 32123969 DOI: 10.1007/s00259-020-04709-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
320 Sabet A, Haghighiabyaneh M, Rajyaguru C, Raisinghani A, Kupsky D, Demaria AN. Carcinoid Heart Disease. Structural Heart 2020;4:78-86. [DOI: 10.1080/24748706.2020.1715517] [Reference Citation Analysis]
321 Benson AB 3rd, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas 2020;49:408-12. [PMID: 32132510 DOI: 10.1097/MPA.0000000000001496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Lahner H, Führer D. Neuroendokrine Neoplasien. Onkologe 2020;26:261-269. [DOI: 10.1007/s00761-019-00705-5] [Reference Citation Analysis]
323 Lahner H, Führer D. Neuroendokrine Neoplasien des Gastrointestinaltrakts. Gastroenterologe 2020;15:129-141. [DOI: 10.1007/s11377-020-00428-9] [Reference Citation Analysis]
324 Sirohi B, Barreto SG, Shrikhande SV, Bhandare M, Bal M, Chacko RT, Bhatia V, Basu S, Thulkar S, Kaur T, Dhaliwal RS, Rath GK. Indian Council of Medical Research Consensus Document for the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Indian Journal of Medical and Paediatric Oncology 2020;41:166-172. [DOI: 10.4103/ijmpo.ijmpo_165_19] [Reference Citation Analysis]
325 Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci 2020;21:E1682. [PMID: 32121432 DOI: 10.3390/ijms21051682] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 21.7] [Reference Citation Analysis]
326 Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med 2020;34:244-53. [PMID: 32114682 DOI: 10.1007/s12149-020-01440-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
327 Mogl MT, Dobrindt EM, Buschermöhle J, Bures C, Pratschke J, Amthauer H, Wetz C, Jann H. Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis. Visc Med 2020;36:20-7. [PMID: 32110653 DOI: 10.1159/000505500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
328 Kanazawa Y, Kikuchi M, Imai Y, Katakami N, Kaihara S, Shinohara S. Successful Treatment of a Mixed Neuroendocrine-Nonneuroendocrine Neoplasm of the Colon with Metastases to the Thyroid Gland and Liver. Case Rep Otolaryngol. 2020;2020:5927610. [PMID: 32099708 DOI: 10.1155/2020/5927610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
329 Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Walter MA. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. JAMA Oncol 2019;5:480-9. [PMID: 30763436 DOI: 10.1001/jamaoncol.2018.6720] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
330 Faggiano A. L’indicazione chirurgica delle neoplasie neuroendocrine del pancreas associate a MEN 1 si basa su dimensioni del tumore e curva di crescita. L'Endocrinologo 2020;21:51-52. [DOI: 10.1007/s40619-020-00658-7] [Reference Citation Analysis]
331 Mayer K, Kiry S, Yordanova A, Ahmadzadehfar H, Gaertner FC, Bundschuh RA, Essler M, Gonzalez-Carmona MA, Strassburg CP, Matthaei H, Lingohr P, Bisht S, Brossart P, Feldmann G. Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. Int J Endocrinol 2020;2020:1491475. [PMID: 32089680 DOI: 10.1155/2020/1491475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
332 Jalbert JJ, Casciano R, Meng J, Brais LK, Pulgar SJ, Berthon A, Dinet J, Kulke MH. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. Oncologist 2020;25:e644-50. [PMID: 31999024 DOI: 10.1634/theoncologist.2019-0691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
333 Kunikowska J, Zemczak A, Kołodziej M, Gut P, Łoń I, Pawlak D, Mikołajczak R, Kamiński G, Ruchała M, Kos-Kudła B, Królicki L. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging 2020;47:922-33. [PMID: 31980909 DOI: 10.1007/s00259-020-04690-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
334 Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020;26:2290-2296. [PMID: 31969335 DOI: 10.1158/1078-0432.ccr-19-3356] [Cited by in Crossref: 131] [Cited by in F6Publishing: 142] [Article Influence: 43.7] [Reference Citation Analysis]
335 Jha A, Patel M, Baker E, Gonzales MK, Ling A, Millo C, Knue M, Civelek AC, Pacak K. Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. Nucl Med Mol Imaging 2020;54:48-52. [PMID: 32206131 DOI: 10.1007/s13139-019-00629-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
336 Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
337 Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2020;26:2011-21. [PMID: 31937620 DOI: 10.1158/1078-0432.CCR-19-2884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
338 Gut P. Liver metastases in gastroenteropancreatic neuroendocrine tumours - treatment methods. Prz Gastroenterol 2020;15:207-14. [PMID: 33005265 DOI: 10.5114/pg.2020.91501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
339 Schwertner A, Bergsland EK, Hope TA, Nakakura EK, Anwar M, Kohi MP, Fidelman N. Neuroendocrine Neoplasms. Image-Guided Interventions in Oncology 2020. [DOI: 10.1007/978-3-030-48767-6_10] [Reference Citation Analysis]
340 Asban A, Patel AJ, Reddy S, Wang T, Balentine CJ, Chen H. Cancer of the Endocrine System. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00068-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
341 Yordanova A. Peptide Receptor Radionuclide Therapy. Clinical Nuclear Medicine 2020. [DOI: 10.1007/978-3-030-39457-8_32] [Reference Citation Analysis]
342 Lyle MA, Connolly HM. Right Heart Failure from Carcinoid Syndrome. Clinical Cases in Right Heart Failure 2020. [DOI: 10.1007/978-3-030-38662-7_8] [Reference Citation Analysis]
343 White RR, Menon VG. Benign and Malignant Tumors of the Liver. Principles and Practice of Geriatric Surgery 2020. [DOI: 10.1007/978-3-319-47771-8_57] [Reference Citation Analysis]
344 Gotfrit J, Asmis T. Gastroenteropancreatic Neuroendocrine Neoplasms. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65749-5] [Reference Citation Analysis]
345 Sellers MM, Greenstein AJ. Cancer of the Small Bowel. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00073-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
346 Krupinova Y, Aboishava L, Gorbacheva A, Kalinin D, Degtyarev M, Eremkina A, Mokrysheva N. Management of pancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia type 1. Clinical case and literature review. Profil med 2020;23:101. [DOI: 10.17116/profmed202023061101] [Reference Citation Analysis]
347 Khorasani M, Law CHL, Myrehaug S, Singh S, Assal A, Hsieh E, Cukier M, Hallet J. Neuroendocrine Tumors (Gastroenteropancreatic). Surgical Oncology Manual 2020. [DOI: 10.1007/978-3-030-48363-0_18] [Reference Citation Analysis]
348 Takatsu F, Ohashi R, Okada N, Sakamoto A, Yagi T, Matsuda N, Ichihara S, Otani H, Yano M, Mizobuchi K. Primary Neuroendocrine Carcinoma of the Appendix. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2020;53:46-53. [DOI: 10.5833/jjgs.2018.0154] [Reference Citation Analysis]
349 Lambregts DMJ, Giammarile F. Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. Imaging and Interventional Radiology for Radiation Oncology 2020. [DOI: 10.1007/978-3-030-38261-2_25] [Reference Citation Analysis]
350 Lepage C. Épidémiologie des tumeurs neuroendocrines intestinales. Oncol 2020. [DOI: 10.3166/onco-2019-0051] [Reference Citation Analysis]
351 Hsieh JC, Chen GY, Jhou DD, Chou WC, Yeh CN, Hwang TL, Lin HC, Chu HC, Wang HM, Yen TC, Chen JS, Wu MH. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors. Sci Rep 2019;9:19917. [PMID: 31882775 DOI: 10.1038/s41598-019-56539-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
352 Shen C, He J, Le X, Zheng L, Cao D. Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema. Onco Targets Ther 2019;12:11339-44. [PMID: 31920326 DOI: 10.2147/OTT.S237634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
353 Panzuto F, Pusceddu S, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, Tafuto S, Manuzzi L, Di Sarno A, Annibale B, de Braud F, Campana D; Itanet (Italian Association for Neuroendocrine Tumours). Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology 2019;19:1067-73. [PMID: 31587962 DOI: 10.1016/j.pan.2019.09.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
354 Hassan SA, Palaskas NL, Agha AM, Iliescu C, Lopez-Mattei J, Chen C, Zheng H, Yusuf SW. Carcinoid Heart Disease: a Comprehensive Review. Curr Cardiol Rep 2019;21:140. [PMID: 31745664 DOI: 10.1007/s11886-019-1207-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
355 Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine 2020;67:9-19. [PMID: 31734779 DOI: 10.1007/s12020-019-02131-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
356 Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934-946. [PMID: 31707430 DOI: 10.1007/s00259-019-04567-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 14.5] [Reference Citation Analysis]
357 Bongiovanni A, Liverani C, Recine F, Mercatali L, Severi S, Ibrahim T. Comment on the Paper by Lemelin et al. Entitled "Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study". Neuroendocrinology 2020;110:721-2. [PMID: 31689704 DOI: 10.1159/000504550] [Reference Citation Analysis]
358 Ström T, Kozlovacki G, Myrenfors P, Almquist M. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET). Patient Prefer Adherence 2019;13:1799-807. [PMID: 31695341 DOI: 10.2147/PPA.S213472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
359 Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, Pusceddu S, Massironi S, Lamberti G, Rinzivillo M, Faggiano A, Spallanzani A, Ferone D, Prinzi N, Rossi RE, Annibale B, Colao AM, Campana D. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist 2020;25:259-65. [PMID: 32162819 DOI: 10.1634/theoncologist.2019-0403] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
360 Isyangulova AZ, Khasanov RS, Enikeev RF, Gordiev MG. TREATMENT OF PATIENTS WITH PANCREATIC NEUROENDOCRINE TUMOURS DEPENDING ON THE DIFFERENTIATION GRADE. Sib onkol ž 2019;18:80-85. [DOI: 10.21294/1814-4861-2019-18-5-80-85] [Reference Citation Analysis]
361 Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2019;13:1023-31. [PMID: 31652074 DOI: 10.1080/17474124.2019.1685381] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
362 Zekri J, Rasool HJ, Meliti A, Rasool J. Neuroendocrine tumor of the kidney: Diagnostic challenge and successful therapy. Urol Ann 2019;11:435-8. [PMID: 31649468 DOI: 10.4103/UA.UA_169_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
363 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
364 Kamei K, Shindoh J, Kiya Y, Matsumoto I, Hashimoto M, Takeyama Y. Conversion surgery after extensive chemotherapy for stage IV mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: clinical implications from the patterns of response and recurrence. Clin J Gastroenterol 2020;13:240-6. [PMID: 31617127 DOI: 10.1007/s12328-019-01053-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
365 Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, Pacak K. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel) 2019;11:E1505. [PMID: 31597347 DOI: 10.3390/cancers11101505] [Cited by in Crossref: 70] [Cited by in F6Publishing: 82] [Article Influence: 17.5] [Reference Citation Analysis]
366 Pozas J, San Román M, Alonso-Gordoa T, Pozas M, Caracuel L, Carrato A, Molina-Cerrillo J. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. Int J Mol Sci 2019;20:E4949. [PMID: 31597249 DOI: 10.3390/ijms20194949] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
367 Bresciani G, Hofland LJ, Dogan F, Giamas G, Gagliano T, Zatelli MC. Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. Front Endocrinol (Lausanne) 2019;10:682. [PMID: 31636608 DOI: 10.3389/fendo.2019.00682] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
368 Huynh L, Cai B, Cheng M, Lax A, Lejeune D, Duh MS, Kim MK. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. Pancreas 2019;48:1126-35. [PMID: 31593022 DOI: 10.1097/MPA.0000000000001403] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
369 Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. Indian J Gastroenterol 2019;38:399-410. [PMID: 31802438 DOI: 10.1007/s12664-019-00957-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
370 Feretis M, Wang T, Ghorani E, Balakrishnan A, Harper SJ, Jah A, Huguet EL, Praseedom RK, Liau SS. A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours. Pancreatology 2019;19:1000-7. [PMID: 31445889 DOI: 10.1016/j.pan.2019.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
371 Hendifar AE, Ramirez RA, Anthony LB, Liu E. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas 2019;48:1111-8. [PMID: 31609931 DOI: 10.1097/MPA.0000000000001391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
372 Medina Ó, Mendoza F, Andrade D, Cabrales E, Ordoñez N. Crisis carcinoide en el postoperatorio de un paciente con enfermedad cardiaca carcinoide. Acta Colombiana de Cuidado Intensivo 2019;19:263-270. [DOI: 10.1016/j.acci.2019.05.002] [Reference Citation Analysis]
373 Laskaratos FM, Armeni E, Shah H, Megapanou M, Papantoniou D, Hayes AR, Navalkissoor S, Gnanasegaran G, von Stempel C, Phillips E, Furnace M, Kamieniarz L, Kousteni M, Luong TV, Watkins J, Mandair D, Caplin M, Toumpanakis C. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms. Endocrine 2020;67:233-42. [PMID: 31556004 DOI: 10.1007/s12020-019-02086-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
374 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
375 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
376 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
377 Bundschuh RA, Habacha B, Lütje S, Essler M. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons. J Clin Med 2019;8:E1474. [PMID: 31527438 DOI: 10.3390/jcm8091474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
378 Kulkarni RS, Anand AS, Parikh SK, Panchal HP, Patel AA, Mehta DP, Patel P. Clinical and epidemiological profile of neuroendocrine tumors: An experience from a regional cancer center from Western India. South Asian J Cancer 2019;8:198-202. [PMID: 31489301 DOI: 10.4103/sajc.sajc_364_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
379 Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, Öberg K, Hellman P, Norlén O, Stålberg P. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. JAMA Oncol 2018;4:183-9. [PMID: 29049611 DOI: 10.1001/jamaoncol.2017.3326] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 13.5] [Reference Citation Analysis]
380 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14: 471-482. [PMID: 30096273 DOI: 10.1200/jop.18.00135] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
381 Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019;35:468-77. [PMID: 31306159 DOI: 10.1097/MOG.0000000000000571] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
382 Gabrielsen J, Girone G, Bennett B, Jung A. Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors. J Adv Pract Oncol 2019;10:646-59. [PMID: 33391850 DOI: 10.6004/jadpro.2019.10.7.2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 Chen L, Chen J. Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. Journal of Pancreatology 2019;2:91-9. [DOI: 10.1097/jp9.0000000000000023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
384 Lim KHJ, Valle JW, Lamarca A. Unusual skull base metastasis from neuroendocrine tumor: a case report. J Med Case Rep 2019;13:273. [PMID: 31466520 DOI: 10.1186/s13256-019-2214-5] [Reference Citation Analysis]
385 Kajtazi Y, Kaemmerer D, Sänger J, Schulz S, Lupp A. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours. J Cancer Res Clin Oncol 2019;145:2481-93. [PMID: 31451931 DOI: 10.1007/s00432-019-03011-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
386 Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clin Cancer Res 2019;25:6939-47. [PMID: 31439583 DOI: 10.1158/1078-0432.CCR-19-1026] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
387 Jhawar S, Lakhotia R, Suzuki M, Welch J, Agarwal SK, Sharretts J, Merino M, Ahlman M, Blau JE, Simonds WF, Del Rivero J. Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM190040. [PMID: 31480016 DOI: 10.1530/EDM-19-0040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
388 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
389 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
390 Farooqui ZA, Chauhan A. Neuroendocrine Tumors in Pediatrics. Glob Pediatr Health 2019;6:2333794X19862712. [PMID: 31384627 DOI: 10.1177/2333794X19862712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
391 Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. J Clin Oncol 2019;37:2571-80. [PMID: 31390276 DOI: 10.1200/JCO.19.00980] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
392 Santos AP, Vinagre J, Soares P, Claro I, Sanches AC, Gomes L, Fernandes I, Catarino AL, Preto J, Pereira BD, Marques AP, Rodrigues F, Amaral C, Rocha G, Mellidez JC, Simões H, Lopes JM, Bugalho MJ; On behalf of the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism . Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol 2019;2019:4518742. [PMID: 31467527 DOI: 10.1155/2019/4518742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
393 Fossmark R, Balto TM, Martinsen TC, Grønbech JE, Munkvold B, Mjønes PG, Waldum HL. Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. Scand J Gastroenterol 2019;54:1003-7. [PMID: 31368380 DOI: 10.1080/00365521.2019.1647281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
394 Endocrine and metabolic complications of advanced cancer. Oxford Handbook of Palliative Care 2019. [DOI: 10.1093/med/9780198745655.003.0015] [Reference Citation Analysis]
395 Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
396 Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:2252-9. [PMID: 31338547 DOI: 10.1007/s00259-019-04431-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
397 Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist 2019;24:e1315-20. [PMID: 31332100 DOI: 10.1634/theoncologist.2018-0675] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
398 Bergeron E, Bensoussan M. Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus.Int J Surg Case Rep. 2019;61:107-110. [PMID: 31352317 DOI: 10.1016/j.ijscr.2019.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
399 Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
400 Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Systemic treatment for lung carcinoids: from bench to bedside. Clin Transl Med 2019;8:22. [PMID: 31273555 DOI: 10.1186/s40169-019-0238-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
401 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
402 Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 2019;19:575. [PMID: 31196127 DOI: 10.1186/s12885-019-5794-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
403 Williamson LM, Steel M, Grewal JK, Thibodeau ML, Zhao EY, Loree JM, Yang KC, Gorski SM, Mungall AJ, Mungall KL, Moore RA, Marra MA, Laskin J, Renouf DJ, Schaeffer DF, Jones SJM. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. Cold Spring Harb Mol Case Stud 2019;5:a003814. [PMID: 31160355 DOI: 10.1101/mcs.a003814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
404 Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki KI, Kolomodi D, Kaltsas G, Koumarianou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019;8:641-653. [PMID: 31026812 DOI: 10.1530/ec-19-0134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
405 Kitade H, Ohtsubo K, Hokkoku K, Mori M, Osamura RY, Sakuma H, Nakai M, Yano S. A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Int Cancer Conf J 2019;8:24-8. [PMID: 31149542 DOI: 10.1007/s13691-018-0348-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
406 Liu T, Liao J, Dang J, Li G. Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919853673. [PMID: 31191714 DOI: 10.1177/1758835919853673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
407 Farina DA, Krogh KM, Boike JR. Chronic Diarrhea Secondary to Newly Diagnosed VIPoma. Case Rep Gastroenterol 2019;13:225-9. [PMID: 31123451 DOI: 10.1159/000494554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
408 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
409 Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Gálvez Moreno MÁ, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ. Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. Horm Cancer 2019;10:107-19. [PMID: 31102172 DOI: 10.1007/s12672-019-00361-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
410 Shilkrut M, Sapir E, Hanasoge S, Schipper MJ, Normolle DP, Ben-Josef E, Ensminger W, Lawrence TS, Feng M. Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 2018;41:326-31. [PMID: 26886946 DOI: 10.1097/COC.0000000000000276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Wang X, Zhou N, Xiao Y, Zhu W, Bai C, Zhao L. Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report. Oncologist 2019;24:e793-7. [PMID: 31073023 DOI: 10.1634/theoncologist.2018-0855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
412 Luo Y, Ameli S, Pandey A, Khoshpouri P, Ghasabeh MA, Pandey P, Li Z, Hu D, Kamel IR. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019;29:5804-5812. [PMID: 31073860 DOI: 10.1007/s00330-019-06246-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
413 Cahajlová R, Černá M, Kiňová S. Multimodal treatment of thymic carcinoid: a case report. Vnitr Lek 2019;65:363-368. [DOI: 10.36290/vnl.2019.065] [Reference Citation Analysis]
414 Brighi N, Lamberti G, Maggio I, Manuzzi L, Ricci C, Casadei R, Santini D, Mosconi C, Lisotti A, Ambrosini V, Pantaleo MA, Campana D. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig Liver Dis 2019;51:689-94. [PMID: 30314949 DOI: 10.1016/j.dld.2018.09.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
415 Bournaud C, Lombard-bohas C, Habouzit V, Carlier T, Hindié E, Ansquer C. La radiothérapie interne vectorisée par les analogues de la somatostatine, en pratique, en 2019. Médecine Nucléaire 2019;43:251-266. [DOI: 10.1016/j.mednuc.2019.04.001] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
416 Baudin E, Hadoux J, de Baere T, Berdelou A, Tselikas L, Caramella C, Terroir M, Boige V, Goere D, Faron M, Deschamps F, Burtin P, Leboulleux S, Malka D, Scoazec J, Ducreux M. Traitement des néoplasmes neuroendocrines digestifs. Oncol 2019;21:97-103. [DOI: 10.3166/onco-2019-0049] [Reference Citation Analysis]
417 Chan LL, Chan SL. Systemic treatment of pancreatic neuroendocrine tumors. Surg Pract 2019;23:48-58. [DOI: 10.1111/1744-1633.12351] [Reference Citation Analysis]
418 Kurita Y, Kuwahara T, Mizuno N, Okuno N, Matsumoto S, Toriyama K, Koda H, Obata M, Hijioka S, Shimizu Y, Inaba Y, Nakajima A, Kubota K, Hara K. Utility of somatostatin receptor scintigraphy in pancreatic neuroendocrine neoplasms. Journal of the Japan Pancreas Society 2019;34:78-85. [DOI: 10.2958/suizo.34.78] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
419 Klink AJ, Feinberg B, Yu HT, Ray D, Pulgar S, Phan A, Vinik A. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. Oncologist 2019;24:1331-9. [PMID: 31015313 DOI: 10.1634/theoncologist.2018-0798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
420 You Y, Jang JY, Kim SC, Yoon YS, Park JS, Cho CK, Park SJ, Yang JD, Lee WJ, Hong TH, Ahn KS, Jeong CY, Lee HK, Lee SE, Roh YH, Kim HJ, Kim H, Han IW. Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database. Cancer Res Treat. 2019;51:1639-1652. [PMID: 30999719 DOI: 10.4143/crt.2019.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
421 Hamano Y, Moriwaki T, To K, Watahiki T, Yamada T, Sakashita S, Hyodo I. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression. Intern Med 2019;58:1087-91. [PMID: 30568142 DOI: 10.2169/internalmedicine.1809-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
422 Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.J Oncol Pharm Pract. 2019;25:1425-1433. [PMID: 30924737 DOI: 10.1177/1078155219839458] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
423 Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer 2019;19:274. [PMID: 30922252 DOI: 10.1186/s12885-019-5459-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
424 Kaçmaz E, Heidsma CM, Besselink MGH, Dreijerink KMA, Klümpen HJ, Nieveen van Dijkum EJM, Engelsman AF. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E403. [PMID: 30909512 DOI: 10.3390/jcm8030403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
425 Annese T, Tamma R, Ruggieri S, Ribatti D. Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers (Basel) 2019;11:E381. [PMID: 30889903 DOI: 10.3390/cancers11030381] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
426 Fagan R, Bokhari SSN, Inayat F. Vitamin D and vitamin B12 deficiencies in patients with small intestinal carcinoid tumour: is opioid use disorder a confounding factor in the diagnosis? BMJ Case Rep 2019;12:e227430. [PMID: 30878964 DOI: 10.1136/bcr-2018-227430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
427 Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol 2019; 25(10): 1171-1184 [PMID: 30886501 DOI: 10.3748/wjg.v25.i10.1171] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
428 Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. Endocr Pract 2019;25:580-8. [PMID: 30865533 DOI: 10.4158/EP-2018-0603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
429 Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, Keutgen X. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases. Int J Endocrinol. 2019;2019:9871319. [PMID: 30992703 DOI: 10.1155/2019/9871319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
430 Rendell MS. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. Drug Des Devel Ther 2019;13:817-24. [PMID: 30880915 DOI: 10.2147/DDDT.S144556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
431 Woltering EA, Voros BA, Beyer DT, Thiagarajan R, Ramirez RA, Mamikunian G, Boudreaux JP. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel. Pancreas 2019;48:356-62. [PMID: 30768573 DOI: 10.1097/MPA.0000000000001263] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
432 Rinke A, Gress TM. Neuroendokrine Tumoren des Pankreas. Internist 2019;60:247-256. [DOI: 10.1007/s00108-018-0545-8] [Reference Citation Analysis]
433 Granberg D. Bronchial carcinoids. International Journal of Endocrine Oncology 2019;6:IJE16. [DOI: 10.2217/ije-2017-0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
434 Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 2019;12:1717-28. [PMID: 30881026 DOI: 10.2147/OTT.S182259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
435 Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, Gonzales MK, Viana B, Alrezk R, Adams KT, Tena I, Chen A, Neuzil J, Raygada M, Kebebew E, Taieb D, O'Dorisio MS, O'Dorisio T, Civelek AC, Stratakis CA, Mercado-Asis L, Pacak K. Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Front Oncol 2019;9:53. [PMID: 30854332 DOI: 10.3389/fonc.2019.00053] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
436 Goto Y, Motoi N. Neuroendocrine Tumor of Lung and Mediastinum: the Updated Pathological Diagnosis and Treatment. JJLC 2019;59:37-45. [DOI: 10.2482/haigan.59.37] [Reference Citation Analysis]
437 Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Ther Adv Endocrinol Metab 2019;10:2042018819828217. [PMID: 30815246 DOI: 10.1177/2042018819828217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
438 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
439 Maqsood MH, Tameez Ud Din A, Khan AH. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Cureus. 2019;11:e3986. [PMID: 30972265 DOI: 10.7759/cureus.3986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
440 Wang Z, Cheng S, Zhou F, Han X, Lu X, Sun D, Zhang X. [Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor]. Zhongguo Fei Ai Za Zhi 2019;22:34-9. [PMID: 30674391 DOI: 10.3779/j.issn.1009-3419.2019.01.07] [Reference Citation Analysis]
441 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 112] [Cited by in F6Publishing: 119] [Article Influence: 28.0] [Reference Citation Analysis]
442 Akahori H. Clinical remission of an inoperable malignant insulinoma by the combination treatment with octreotide and everolimus. J Gen Fam Med 2019;20:107-10. [PMID: 31065475 DOI: 10.1002/jgf2.235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
443 Forrer F. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Nuclear Medicine Therapy 2019. [DOI: 10.1007/978-3-030-17494-1_4] [Reference Citation Analysis]
444 Yim KL, Thomas BM, Christian A. Clinical Approaches to the Management of Neuroendocrine Tumours. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_38] [Reference Citation Analysis]
445 Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 2019;10:17-29. [PMID: 30713600 DOI: 10.18632/oncotarget.26523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
446 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Campagnaro T, Ercolani G, Conci S, Giuliante F, Dore A, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Guglielmi A, Iacono C. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. J Gastrointest Surg 2019;23:93-100. [PMID: 30242647 DOI: 10.1007/s11605-018-3973-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
447 Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M, Lupescu I, Dima SO, Buica F, Dumitrascu T, Lungulescu C, Croitoru VM, Tanase A, Negru SM, Gramaticu IM. LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. Acta Endocrinol (Buchar) 2019;15:390-7. [PMID: 32010361 DOI: 10.4183/aeb.2019.390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
448 李 梦. Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms. ACM 2019;09:225-234. [DOI: 10.12677/acm.2019.93035] [Reference Citation Analysis]
449 Eulitz N, Lauinger E. Palliative Therapie der Dysphagie. Palliative Viszeralchirurgie 2019. [DOI: 10.1007/978-3-662-57362-4_13] [Reference Citation Analysis]
450 Dillhoff ME, Ellison EC. Zollinger-Ellison Syndrome. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00060-1] [Reference Citation Analysis]
451 Barreto JC, Posner MC. Management of Secondary Hepatic Neoplasms. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00134-5] [Reference Citation Analysis]
452 Fisher GA. Gastroenteropancreatic Neuroendocrine Tumors. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_16] [Reference Citation Analysis]
453 Bösch F, Auernhammer C, Spitzweg C, Angele M. Gastroenteropancreatic Neuroendocrine Tumours. Gastroenterology For General Surgeons 2019. [DOI: 10.1007/978-3-319-92768-8_3] [Reference Citation Analysis]
454 Tadman M, Davies P, Whyand T, Martin L. Neuroendocrine Tumours. Advanced Practice in Endocrinology Nursing 2019. [DOI: 10.1007/978-3-319-99817-6_65] [Reference Citation Analysis]
455 Cives M, Pellè E, Silvestris F, Strosberg J. Management of NETs in the Precision Medicine Era. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00041-7] [Reference Citation Analysis]
456 Moore AR, Yip VS. Treatment of Neuroendocrine Tumour Disease. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_20] [Reference Citation Analysis]
457 Chatzellis E, Kaltsas G. Somatostatin Receptor Expression in Gastrointestinal Tumors. Encyclopedia of Endocrine Diseases 2019. [DOI: 10.1016/b978-0-12-801238-3.64282-4] [Reference Citation Analysis]
458 Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
459 Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers (Basel) 2018;10:E510. [PMID: 30545054 DOI: 10.3390/cancers10120510] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
460 Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine (Baltimore) 2018;97:e13390. [PMID: 30461659 DOI: 10.1097/MD.0000000000013390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
461 Kang J, Yoo C, Hwang HS, Hong SM, Kim KP, Kim SY, Hong YS, Kim TW, Ryoo BY. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Invest New Drugs 2019;37:763-70. [PMID: 30536151 DOI: 10.1007/s10637-018-0710-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
462 Ge W, Zhou D, Zhu L, Song W, Wang W. Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors. J Cancer 2018;9:4783-90. [PMID: 30588264 DOI: 10.7150/jca.25908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
463 González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clin Transl Oncol 2019;21:55-63. [PMID: 30535553 DOI: 10.1007/s12094-018-1980-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
464 Fouché M, Bouffard Y, Le Goff MC, Prothet J, Malavieille F, Sagnard P, Christin F, Hayi-Slayman D, Pasquer A, Poncet G, Walter T, Rimmelé T. Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery. Endocr Connect 2018;7:1245-50. [PMID: 30352418 DOI: 10.1530/EC-18-0324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
465 Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
466 Fottner C, Weber M. Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts. Wien klin Mag 2018;21:250-259. [DOI: 10.1007/s00740-018-0238-x] [Reference Citation Analysis]
467 Esin E, Oksuzoglu B, Erdur E, Ozgun G, Demirci U. Well differentiated neuroendocrine tumors, a single center experience. Journal of Oncological Sciences 2018;4:119-24. [DOI: 10.1016/j.jons.2018.10.002] [Reference Citation Analysis]
468 Wu Q, Chen B, Yan G, Yang Z, Xiong L, He J. A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors. Onco Targets Ther 2018;11:7655-68. [PMID: 30464514 DOI: 10.2147/OTT.S181335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
469 Kiesewetter B, Raderer M. My burning issues in neuroendocrine tumours (NET). Memo 2018;11:313-6. [PMID: 30595757 DOI: 10.1007/s12254-018-0449-2] [Reference Citation Analysis]
470 Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. Curr Treat Options Oncol 2018;19:69. [PMID: 30397729 DOI: 10.1007/s11864-018-0592-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
471 Uccella S, La Rosa S, Volante M, Papotti M. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocr Pathol. 2018;29:150-168. [PMID: 29520563 DOI: 10.1007/s12022-018-9522-y] [Cited by in Crossref: 65] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
472 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
473 Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist 2019;24:463-74. [PMID: 30355775 DOI: 10.1634/theoncologist.2018-0217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
474 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
475 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
476 Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord 2017;18:381-91. [PMID: 28871510 DOI: 10.1007/s11154-017-9428-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
477 Saif MW, Fu J, Smith MH, Weinstein B, Relias V, Daly KP. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Pancreat Cancer 2018;4:64-71. [PMID: 30788459 DOI: 10.1089/pancan.2018.0013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
478 Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study. Invest New Drugs 2019;37:573-8. [PMID: 30267338 DOI: 10.1007/s10637-018-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
479 van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46:704-717. [PMID: 30267116 DOI: 10.1007/s00259-018-4158-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
480 Nölting S, Grossman A, Pacak K. Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Exp Clin Endocrinol Diabetes 2019;127:117-28. [PMID: 30235495 DOI: 10.1055/a-0715-1888] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
481 Byrne RM, Pommier RF. Small Bowel and Colorectal Carcinoids. Clin Colon Rectal Surg. 2018;31:301-308. [PMID: 30186052 DOI: 10.1055/s-0038-1642054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
482 Agasarova A, Harnett C, Mulligan N, Majeed MS, Caimo A, Tamagno G. Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries. Int J Endocrinol 2018;2018:1043287. [PMID: 30228817 DOI: 10.1155/2018/1043287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
483 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
484 Kagawa Y, Kitaguchi S, Moriwaki K, Osaki N, Yamane T, Sugahara F. The Successful Use of Somatostatin Receptor Scintigraphy to Determine the Treatment Strategy for Lung Typical Carcinoid. JJLC 2018;58:286-291. [DOI: 10.2482/haigan.58.286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
485 Norlén O, Montan H, Hellman P, Stålberg P, Sundin A. Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. World J Surg 2018;42:498-505. [PMID: 29159606 DOI: 10.1007/s00268-017-4364-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
486 Hendifar AE, Dhall D, Strosberg JR. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist 2019;24:54-61. [PMID: 30104288 DOI: 10.1634/theoncologist.2018-0187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
487 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
488 Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. Oncologist 2019;24:47-53. [PMID: 30072388 DOI: 10.1634/theoncologist.2017-0651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
489 Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 2017;12:757-74. [PMID: 29143176 DOI: 10.1007/s11523-017-0532-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
490 Wagner M, Samaha D, Cuervo J, Patel H, Martinez M, O'Neil WM, Jimenez-Fonseca P. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context. Adv Ther 2018;35:1215-31. [PMID: 29987525 DOI: 10.1007/s12325-018-0745-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
491 Sasaki S, Kurata T, Hagino S, Shoji Y, Terada I, Yoshikawa A, Kitagawa H, Fujimura T, Izumi R, Saito K. Peritoneal Metastasis Detected 16 Years after Primary Operation for Gastric Neuroendocrine Tumor. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2018;51:520-528. [DOI: 10.5833/jjgs.2017.0176] [Reference Citation Analysis]
492 Woltering EA, Voros BA, Thiagarajan R, Beyer DT, Ramirez RA, Wang YZ, Mamikunian G, Boudreaux JP. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel. Pancreas 2018;47:843-8. [PMID: 29939909 DOI: 10.1097/MPA.0000000000001092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
493 Mulvey CK, Bergsland EK. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. JOP 2018;14:487-489. [DOI: 10.1200/jop.18.00440] [Reference Citation Analysis]
494 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
495 Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16. [PMID: 30009041 DOI: 10.1186/s40842-018-0066-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
496 Døssing KBV, Kjær C, Vikeså J, Binderup T, Knigge U, Culler MD, Kjær A, Federspiel B, Friis-Hansen L. Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes (Basel) 2018;9:E337. [PMID: 29973528 DOI: 10.3390/genes9070337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
497 Alshaikh OM, Asa SL, Mete O, Greig PD, Mcgilvray I, Ezzat S. Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. AACE Clinical Case Reports 2018;4:e289-e293. [DOI: 10.4158/accr-2017-0128] [Reference Citation Analysis]
498 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
499 Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal 2018; 6(2): 9-20 [DOI: 10.13105/wjma.v6.i2.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
500 Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018;18:84. [PMID: 29902988 DOI: 10.1186/s12876-018-0817-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
501 Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol 2018;25:S86-93. [PMID: 29910651 DOI: 10.3747/co.25.3808] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
502 Luo Y, Chen J, Shen B, Wang M, Cai H, Xu L, Chen L, Chen M, Li ZP, Feng ST. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? Eur Radiol 2018;28:5250-7. [PMID: 29876704 DOI: 10.1007/s00330-018-5512-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
503 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36:2578-2584. [PMID: 29878866 DOI: 10.1200/jco.2018.78.5865] [Cited by in Crossref: 192] [Cited by in F6Publishing: 206] [Article Influence: 38.4] [Reference Citation Analysis]
504 Munakata S, Murai Y, Koizumi A, Kato H, Yamamoto R, Ueda S, Tokuda S, Sakuraba S, Kushida T, Orita H, Sakurada M, Maekawa H, Sato K. Mixed Neuroendocrine Carcinoma and Squamous Cell Carcinoma of the Colon: Case Report and Literature Review. Case Rep Gastroenterol. 2018;12:240-246. [PMID: 30022911 DOI: 10.1159/000488194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
505 Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Hinshaw JL, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 2018;23:1006-e104. [PMID: 29853660 DOI: 10.1634/theoncologist.2018-0294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
506 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
507 Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Oncologist 2019;24:38-46. [PMID: 29794066 DOI: 10.1634/theoncologist.2017-0622] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
508 Rossi RE, Rausa E, Cavalcoli F, Conte D, Massironi S. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scand J Gastroenterol 2018;53:835-42. [PMID: 29726295 DOI: 10.1080/00365521.2018.1468479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
509 Lange F, Kaemmerer D, Behnke-Mursch J, Brück W, Schulz S, Lupp A. Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. J Cancer Res Clin Oncol 2018;144:1227-37. [PMID: 29696364 DOI: 10.1007/s00432-018-2645-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
510 Neyrinck K, Breuls N, Holvoet B, Oosterlinck W, Wolfs E, Vanbilloen H, Gheysens O, Duelen R, Gsell W, Lambrichts I, Himmelreich U, Verfaillie CM, Sampaolesi M, Deroose CM. The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction. Theranostics 2018;8:2799-813. [PMID: 29774076 DOI: 10.7150/thno.22980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
511 Rastogi V, Singh D, Mazza JJ, Parajuli D, Yale SH. Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila. Clin Med Res 2018;16:16-28. [PMID: 29650525 DOI: 10.3121/cmr.2017.1379a] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
512 Exner S, Prasad V, Wiedenmann B, Grötzinger C. Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. Front Endocrinol (Lausanne) 2018;9:146. [PMID: 29681888 DOI: 10.3389/fendo.2018.00146] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
513 Tanno L, Mayo D, Mills S, Takhar A, Cave J, Nolan L, Stedman B, Sundram FX, Abu Hilal M, Connor H, Pearce N, Armstrong T. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology 2018;18:304-12. [PMID: 29433805 DOI: 10.1016/j.pan.2017.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
514 Tsoukalas N, Baxevanos P, Aravantinou-Fatorou E, Tolia M, Galanopoulos M, Tsapakidis K, Kyrgias G, Toumpanakis C, Kaltsas G. Advances on systemic treatment for lung neuroendocrine neoplasms. Ann Transl Med 2018;6:146. [PMID: 29862235 DOI: 10.21037/atm.2018.04.03] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
515 Amoroso V, Pavel M, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A. IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug? Future Oncology 2018;14:897-899. [DOI: 10.2217/fon-2017-0667] [Reference Citation Analysis]
516 Rajeev LK, Asati V, Lokesh KN, Rudresh AH, Babu S, Jacob LA, Lokanatha D, Babu G, Lakshmaiah KC. Cancer of Unknown Primary: Opportunities and Challenges. Indian Journal of Medical and Paediatric Oncology 2018;39:219-226. [DOI: 10.4103/ijmpo.ijmpo_91_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
517 Ricci C, Casadei R, Taffurelli G, Campana D, Ambrosini V, Pacilio CA, Santini D, Brighi N, Minni F. Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. Pancreatology 2018;18:313-7. [PMID: 29487026 DOI: 10.1016/j.pan.2018.02.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
518 Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2018;144:1155-63. [PMID: 29602973 DOI: 10.1007/s00432-018-2636-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
519 Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer 2018;25:607-18. [PMID: 29559553 DOI: 10.1530/ERC-17-0489] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
520 Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget 2017;8:25669-78. [PMID: 27788498 DOI: 10.18632/oncotarget.12900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
521 Partelli S, Cirocchi R, Rancoita PMV, Muffatti F, Andreasi V, Crippa S, Tamburrino D, Falconi M. A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB (Oxford) 2018;20:197-203. [PMID: 29196022 DOI: 10.1016/j.hpb.2017.10.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
522 Philips P, Kooby DA, Maithel S, Merchant NB, Weber SM, Winslow ER, Ahmad S, Kim HJ, Scoggins CR, McMasters KM, Martin RCG 2nd. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors. Pancreas 2018;47:326-31. [PMID: 29351120 DOI: 10.1097/MPA.0000000000000990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
523 Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E. Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology 2018;154:998-1008.e1. [PMID: 29155309 DOI: 10.1053/j.gastro.2017.11.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
524 Walter D, Harter PN, Battke F, Winkelmann R, Schneider M, Holzer K, Koch C, Bojunga J, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Waidmann O. Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors. Sci Rep 2018;8:3811. [PMID: 29491456 DOI: 10.1038/s41598-018-22115-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
525 Kawasaki K, Fujii M, Sato T. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech 2018;11:dmm029595. [PMID: 29590641 DOI: 10.1242/dmm.029595] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
526 Hernández B, Coïc YM, López-Tobar E, Sanchez-Cortes S, Baron B, Pflüger F, Kruglik SG, Cohen R, Ghomi M. Dynamical Behavior of Somatostatin-14 and Its Cyclic Analogues as Analyzed in Bulk and on Plasmonic Silver Nanoparticles. Adv Protein Chem Struct Biol 2018;112:81-121. [PMID: 29680244 DOI: 10.1016/bs.apcsb.2018.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
527 Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, Bartenstein P, Bengel F, Schatka I, Muegge DO, Papp L, Zsótér N, Große-Ophoff T, Essler M, Bundschuh RA. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 2017;8:7039-49. [PMID: 27705948 DOI: 10.18632/oncotarget.12402] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
528 Hainsworth JD, Greco FA. Cancer of Unknown Primary Site. The American Cancer Society's Oncology in Practice 2018. [DOI: 10.1002/9781118592168.ch44] [Reference Citation Analysis]
529 Strosberg J. Gastroenteropancreatic Neuroendocrine Tumors. The American Cancer Society's Oncology in Practice 2018. [DOI: 10.1002/9781118592168.ch39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
530 Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol 2018;14:216-27. [PMID: 29449689 DOI: 10.1038/nrendo.2018.3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
531 Yanagisawa A, Hirano S, Shimizu S, Hiroishi T, Shikano K, Hayama N, Fujita T, Amano H, Nakamura M, Nakamura S, Tabeta H. Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR. Case Rep Oncol Med 2017;2017:1564819. [PMID: 29445555 DOI: 10.1155/2017/1564819] [Reference Citation Analysis]
532 Lewis AR, Wang X, Magdalani L, D’Arienzo P, Bashir C, Mansoor W, Hubner R, Valle JW, McNamara MG. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. World J Gastroenterol 2018; 24(6): 671-679 [PMID: 29456406 DOI: 10.3748/wjg.v24.i6.671] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
533 Kaltsas G, Mukherjee J, Lee K. Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch128] [Reference Citation Analysis]
534 Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018;9:14922-38. [PMID: 29599916 DOI: 10.18632/oncotarget.24464] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
535 Shirota T, Nagakawa Y, Sahara Y, Takishita C, Hijikata Y, Hosokawa Y, Nakajima T, Osakabe H, Katsumata K, Tsuchida A. Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach. Gland Surg 2018;7:12-9. [PMID: 29629315 DOI: 10.21037/gs.2017.11.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
536 Öberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg 2018;7:20-7. [PMID: 29629316 DOI: 10.21037/gs.2017.10.08] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
537 Jiao X, Pulgar S, Boyd M, Braiteh F, Mirakhur B, Pitman Lowenthal S, Fox P, Frytak J, Cox D, Paulson AS. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States. Pancreas 2018;47:173-82. [PMID: 29206668 DOI: 10.1097/MPA.0000000000000955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
538 Fottner C, Weber MM. Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts. Onkologe 2018;24:124-132. [DOI: 10.1007/s00761-017-0310-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
539 Lania A, Lavezzi E, Vitali E, Carnaghi C. I recettori della somatostatina nella terapia dei tumori neuroendocrini del tratto gastroenteropancreatico. L'Endocrinologo 2018;19:21-25. [DOI: 10.1007/s40619-018-0396-5] [Reference Citation Analysis]
540 Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging 2018;18:3. [PMID: 29361984 DOI: 10.1186/s40644-018-0136-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
541 Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol 2018;14:1155-64. [PMID: 29350062 DOI: 10.2217/fon-2017-0340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
542 Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology 2018;106:357-65. [PMID: 29320780 DOI: 10.1159/000486096] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
543 Pusceddu S, De Braud F, Lo Russo G, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget 2016;7:44841-7. [PMID: 27057638 DOI: 10.18632/oncotarget.8601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
544 Cuyle PJ, Prenen H. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol. 2018;31:140-150. [PMID: 29507461 DOI: 10.20524/aog.2018.0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
545 Kaiho-Sakuma M, Toyoshima M, Watanabe M, Toki A, Kameda S, Minato T, Niikura H, Yaegashi N. Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report. Gynecol Oncol Rep 2018;23:20-3. [PMID: 29326972 DOI: 10.1016/j.gore.2018.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
546 Miotto M, Marchegiani G, Zamboni G. Neuroendocrine Pancreatic Tumors. Hepatobiliary and Pancreatic Cancer 2018. [DOI: 10.1007/978-3-319-50296-0_7] [Reference Citation Analysis]
547 Tafuto S, De Divitiis C, Bianco A, Capozzi M, Lassandro F, Tatangelo F, De Rosa N, Ottaiano A, Bergaminelli C, Petrillo A, Di Girolamo E, Di Sarno A. Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_20] [Reference Citation Analysis]
548 Endokrines System und Immunmodulation. Arzneimitteltherapie in der Palliativmedizin 2018. [DOI: 10.1016/b978-3-437-23672-3.00008-1] [Reference Citation Analysis]
549 Chan DL, Segelov E, Singh S. Therapy for Metastatic Disease: Ileum. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_22] [Reference Citation Analysis]
550 Wagner M, Samaha D, Khoury H, O'Neil WM, Lavoie L, Bennetts L, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke MH, Goetghebeur M. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Adv Ther 2018;35:81-99. [PMID: 29270780 DOI: 10.1007/s12325-017-0653-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
551 Fazio N, Rubino M. Therapy for Metastatic Disease with Unknown Primary Tumor. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_24] [Reference Citation Analysis]
552 Raj N, Reidy-Lagunes D. The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges. Pancreas 2018;47:1-5. [PMID: 29232339 DOI: 10.1097/MPA.0000000000000949] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
553 Kim SM, Eads JR. Systemic Therapy for the Management of Neuroendocrine Tumor Liver Metastases. Primary and Metastatic Liver Tumors 2018. [DOI: 10.1007/978-3-319-91977-5_22] [Reference Citation Analysis]
554 Noonan K, Derks J, Laskin J, Dingemans AC. Neuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer. IASLC Thoracic Oncology 2018. [DOI: 10.1016/b978-0-323-52357-8.00055-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
555 Komoto I, Hosoda Y, Imamura M. Molecular Targeted Therapy for Gastroenteropancreatic Neuroendocrine Tumors. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy 2018. [DOI: 10.1007/978-981-10-6469-2_9] [Reference Citation Analysis]
556 Carnaghi C, Smiroldo V. Medical Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumors. Clinical Applications of Nuclear Medicine Targeted Therapy 2018. [DOI: 10.1007/978-3-319-63067-0_21] [Reference Citation Analysis]
557 Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE. The Clinicopathological Aspects of Primary Presacral Neuroendocrine Neoplasms: One Center Experience. Pancreas 2018;47:122-9. [PMID: 29215535 DOI: 10.1097/MPA.0000000000000954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
558 Honselmann KC, Bausch D. Neuroendokrine Tumoren des Pankreas. Evidenzbasierte Chirurgie 2018. [DOI: 10.1007/978-3-662-56533-9_9] [Reference Citation Analysis]
559 Christians KK, Younan G, George B, Tsai S, Evans DB. Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas. Difficult Decisions in Endocrine Surgery 2018. [DOI: 10.1007/978-3-319-92860-9_36] [Reference Citation Analysis]
560 Ettorre GM, Meniconi RL, Hammel P, Deguelte S, Filippi L, Cianni R. Management of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_13] [Reference Citation Analysis]
561 Rassner M, Lahner H, von Bubnoff N, Lammert F. Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). Geriatrische Onkologie 2018. [DOI: 10.1007/978-3-662-48727-3_30] [Reference Citation Analysis]
562 Kakiuchi D, Hada M, Oshima M, Kato Y, Kotake M, Hara T. A Case of a 5-mm Rectal Neuroendocrine Tumor(Grade 1)with Lymph Node Metastases. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2018;79:854-857. [DOI: 10.3919/jjsa.79.854] [Reference Citation Analysis]
563 Öberg K. Therapy for Metastatic Disease: Bronchi. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_23] [Reference Citation Analysis]
564 Ettrich TJ, Seufferlein T. Liver Metastases of Neuroendocrine Tumors and CCC. Locoregional Tumor Therapy 2018. [DOI: 10.1007/978-3-319-69947-9_5] [Reference Citation Analysis]
565 Kos-kudła B, Poczkaj K, Malczewska A. Therapy for Metastatic Disease: Pancreas. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_21] [Reference Citation Analysis]
566 Ferone D, Nazzari E, Grillo F, Sciallero S, Morbelli S, De Cian F, Cittadini G, Albertelli M, Edoardo G. Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_14] [Reference Citation Analysis]
567 Vitale G, Milione M, Prinzi N. Prognostic Factors: Molecular Pathway – Somatostatin Receptors. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_6] [Reference Citation Analysis]
568 La Rosa S, Bongiovanni M, Uccella S. Pathology of Neuroendocrine Neoplasms: Morphological, Immunophenotypical, and Circulating Molecular Markers. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_2] [Reference Citation Analysis]
569 Kidd M, Ferone D, Albertelli M, Nazzari E, Bodei L, Modlin IM. The Molecular Biology of NET: Current Status and Evaluation of Biomarkers for Prediction and Prognosis. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_3] [Reference Citation Analysis]
570 Shiihara M, Izumo W, Higuchi R, Yazawa T, Uemura S, Furukawa T, Yamamoto M. A case of long-survival insulinoma with multiple neuroendocline tumour type 1 controlled by multimodal therapy. J Surg Case Rep 2017;2017:rjx244. [PMID: 29250314 DOI: 10.1093/jscr/rjx244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
571 Memeo R, Roselli S, Lupo L, Cherkaoui Z, Pessaux P. Laparoscopic management of neuroendocrine tumors: state-of-the-art. Transl Gastroenterol Hepatol. 2017;2:109. [PMID: 29354766 DOI: 10.21037/tgh.2017.11.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
572 Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics. 2017;11:115-122. [PMID: 29255345 DOI: 10.2147/btt.s108818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
573 Crabtree JS. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front Endocrinol (Lausanne) 2017;8:341. [PMID: 29255447 DOI: 10.3389/fendo.2017.00341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
574 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
575 Berardi R, Partelli S, Cascinu S, Falconi M. Somatostatin analogs: is one better than other? Ther Adv Med Oncol 2017;9:817-9. [PMID: 29449900 DOI: 10.1177/1758834017741073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
576 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
577 Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol 2017;18:72. [PMID: 29143892 DOI: 10.1007/s11864-017-0514-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
578 Hamiditabar M, Ali M, Roys J, Wolin EM, OʼDorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med 2017;42:436-43. [PMID: 28263217 DOI: 10.1097/RLU.0000000000001629] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
579 Gajate P, Alonso-Gordoa T, Martínez-Sáez O, Molina-Cerrillo J, Grande E. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. Clin Transl Oncol 2018;20:561-9. [PMID: 29124519 DOI: 10.1007/s12094-017-1758-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
580 Gao Y, Wang C, Gao Y, Chen H, Peng B, Chen W, Ran X. Glucagonoma syndrome with serous oligocystic adenoma: A rare case report. Medicine (Baltimore) 2017;96:e8448. [PMID: 29069049 DOI: 10.1097/MD.0000000000008448] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
581 Lepage C. Épidémiologie des tumeurs neuroendocrines intestinales. Colon Rectum 2017;11:207-211. [DOI: 10.1007/s11725-017-0741-z] [Reference Citation Analysis]
582 Walter T. Stratégie thérapeutique des néoplasmes neuroendocrines intestinaux métastatiques. Colon Rectum 2017;11:227-234. [DOI: 10.1007/s11725-017-0743-x] [Reference Citation Analysis]
583 Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. Pancreas 2017;46:1381-5. [PMID: 29040196 DOI: 10.1097/MPA.0000000000000932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
584 Girard N. Neuroendocrine tumors of the thymus: the oncologist point of view. J Thorac Dis 2017;9:S1491-500. [PMID: 29201452 DOI: 10.21037/jtd.2017.08.18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
585 Rozenblum L, Vercellino L, Chougnet CN. Quel bilan d’imagerie fonctionnelle et biologique faire au diagnostic et dans le suivi d’une tumeur neuroendocrine intestinale ? Colon Rectum 2017;11:220-226. [DOI: 10.1007/s11725-017-0739-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
586 Lamberti G, Ceccarelli C, Brighi N, Maggio I, Santini D, Mosconi C, Ricci C, Biasco G, Campana D. Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. Gastroenterol Res Pract 2017;2017:7872519. [PMID: 29213282 DOI: 10.1155/2017/7872519] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
587 Tirosh A, Kebebew E. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 2018;14:111-22. [PMID: 29072093 DOI: 10.2217/fon-2017-0393] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
588 Cioppi F, Cianferotti L, Masi L, Giusti F, Brandi ML. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clin Cases Miner Bone Metab 2017;14:123-30. [PMID: 29263719 DOI: 10.11138/ccmbm/2017.14.1.123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
589 Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, Abdel-Misih SRZ, Dillhoff ME, Sipos JA, Kirschner LS, Shah MH. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017;8:104046-56. [PMID: 29262620 DOI: 10.18632/oncotarget.22001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
590 Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 1510] [Cited by in F6Publishing: 1617] [Article Influence: 251.7] [Reference Citation Analysis]
591 Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther 2017;10:5013-30. [PMID: 29081664 DOI: 10.2147/OTT.S142087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
592 Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018;23:16-24. [PMID: 29038234 DOI: 10.1634/theoncologist.2017-0284] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
593 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
594 Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018;59:66-74. [PMID: 29025982 DOI: 10.2967/jnumed.117.202275] [Cited by in Crossref: 144] [Cited by in F6Publishing: 154] [Article Influence: 24.0] [Reference Citation Analysis]
595 Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Endocrine. 2018;60:15-27. [PMID: 29019150 DOI: 10.1007/s12020-017-1420-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
596 Choi AB, Maxwell JE, Keck KJ, Bellizzi AJ, Dillon JS, OʼDorisio TM, Howe JR. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors? Pancreas 2017;46:1115-20. [PMID: 28902780 DOI: 10.1097/MPA.0000000000000911] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
597 Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med 2017;33:352-6. [PMID: 29177164 DOI: 10.1159/000475831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
598 Aerts M, Reynaert H. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. Case Rep Gastroenterol 2017;11:616-23. [PMID: 29430219 DOI: 10.1159/000485025] [Reference Citation Analysis]
599 Singh S, Sivajohanathan D, Asmis T, Cho C, Hammad N, Law C, Wong R, Zbuk K. Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline. Curr Oncol 2017;24:249-55. [PMID: 28874893 DOI: 10.3747/co.24.3634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
600 Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017;19:9. [PMID: 28220446 DOI: 10.1007/s11912-017-0567-8] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 15.3] [Reference Citation Analysis]
601 Xue M, Shafie A, Qaiser T, Rajpoot NM, Kaltsas G, James S, Gopalakrishnan K, Fisk A, Dimitriadis GK, Grammatopoulos DK, Rabbani N, Thornalley PJ, Weickert MO. Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). Oncotarget 2017;8:76961-73. [PMID: 29100361 DOI: 10.18632/oncotarget.20290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
602 Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res 2017;9:495-503. [PMID: 28860831 DOI: 10.2147/CEOR.S140866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
603 Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol 2017;18:14. [PMID: 28286921 DOI: 10.1007/s11864-017-0461-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
604 OʼToole SM, Drake WM. Response to Somatostatin Analog Therapy in a Patient With von Hippel-Lindau Disease and Multiple Pancreatic Neuroendocrine Tumors. Pancreas 2017;46:e57. [PMID: 28697140 DOI: 10.1097/MPA.0000000000000865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
605 Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57:366-375. [PMID: 28726183 DOI: 10.1007/s12020-017-1360-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
606 Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
607 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017;46:715-31. [PMID: 28609357 DOI: 10.1097/MPA.0000000000000846] [Cited by in Crossref: 186] [Cited by in F6Publishing: 176] [Article Influence: 31.0] [Reference Citation Analysis]
608 Gaikwad V, Patkar S, Barreto SG, Sirohi B, Goel M, Shrikhande SV. Outcomes of 101 Consecutive Surgical Resections of Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs) at Tata Memorial Hospital: a Referral Bias for Nonfunctional Duodenopancreatic Tumours and the Need for Greater Awareness of GEPNETs as a Distinct Entity. Indian J Surg 2017;79:226-33. [PMID: 28659676 DOI: 10.1007/s12262-016-1453-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
609 Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017;46:707-14. [PMID: 28609356 DOI: 10.1097/MPA.0000000000000850] [Cited by in Crossref: 165] [Cited by in F6Publishing: 167] [Article Influence: 27.5] [Reference Citation Analysis]
610 Brieau B, Coriat R. May we challenge the ENETS guidelines in pancreatic neuroendocrine neoplasms? A quiz for French experts. Dig Liver Dis 2017;49:809-19. [PMID: 28377287 DOI: 10.1016/j.dld.2017.03.006] [Reference Citation Analysis]
611 Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE). Endocrine. 2017;57:504-511. [PMID: 28664309 DOI: 10.1007/s12020-017-1355-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
612 Atwal D, Joshi KP, Jeffus S, Ntambi J, Mahmoud F. Well-Differentiated Neuroendocrine Tumor-A Low b-Grade Tumor's Aggressive Course and Dismal Outcome: A Case Report. Perm J 2017;21:16-193. [PMID: 28633725 DOI: 10.7812/TPP/16-193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
613 Hart EA, Meijs TA, Meijer RCA, Dreijerink KM, Tesselaar ME, de Groot CA, Valk GD, Chamuleau SAJ. Carcinoid heart disease: a guide for screening and timing of surgical intervention. Neth Heart J 2017;25:471-8. [PMID: 28631210 DOI: 10.1007/s12471-017-1011-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
614 Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. Digestion 2017;96:13-20. [PMID: 28609761 DOI: 10.1159/000470838] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
615 Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Front Oncol 2017;7:119. [PMID: 28660170 DOI: 10.3389/fonc.2017.00119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
616 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
617 Faggiano A, Circelli L, Colao A, Colantuoni V. I tumori neuroendocrini ereditari. L'Endocrinologo 2017;18:123-129. [DOI: 10.1007/s40619-017-0312-4] [Reference Citation Analysis]
618 Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2017;28:1309-15. [PMID: 28327907 DOI: 10.1093/annonc/mdx078] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 10.3] [Reference Citation Analysis]
619 Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
620 Keck KJ, Choi A, Maxwell JE, Li G, O'Dorisio TM, Breheny P, Bellizzi AM, Howe JR. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Ann Surg Oncol 2017;24:2206-12. [PMID: 28560597 DOI: 10.1245/s10434-017-5899-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
621 Albertelli M, Nazzari E, Sciallero S, Grillo F, Morbelli S, De Cian F, Cittadini G, Ambrosetti E, Ciarmiello A, Ferone D; IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. J Endocrinol Invest 2017;40:1265-9. [PMID: 28550464 DOI: 10.1007/s40618-017-0692-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
622 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
623 Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res 2017;6:663. [PMID: 28529726 DOI: 10.12688/f1000research.10188.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
624 韩露, 崔凯, 欧洋, 李胜. 结肠神经内分泌瘤G2一例个案报道并文献复习. 世界华人消化杂志 2017; 25(13): 1218-1222 [DOI: 10.11569/wcjd.v25.i13.1218] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
625 Ito T, Honma Y, Hijioka S, Kudo A, Fukutomi A, Nozaki A, Kimura Y, Motoi F, Isayama H, Komoto I, Hisamatsu S, Nakajima A, Shimatsu A. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 2017;35:499-508. [PMID: 28470558 DOI: 10.1007/s10637-017-0466-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
626 Derlin T. NETTER-1 Studie zur 177Lu-DOTA-TATE Therapie bei fortgeschrittenen neuroendokrinen Tumoren. Radiologe 2017;57:343-345. [DOI: 10.1007/s00117-017-0221-3] [Reference Citation Analysis]
627 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
628 Fazio N. Watch and wait policy in advanced neuroendocrine tumors: What does it mean? World J Clin Oncol 2017; 8(2): 96-99 [PMID: 28439490 DOI: 10.5306/wjco.v8.i2.96] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
629 Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017;35:1695-1703. [PMID: 28384065 DOI: 10.1200/jco.2016.70.4072] [Cited by in Crossref: 88] [Cited by in F6Publishing: 107] [Article Influence: 14.7] [Reference Citation Analysis]
630 Reidy-lagunes D, Raj N, Saltz L. Commentary: Somatostatin analogs—How we choose, and why. Seminars in Oncology 2017;44:157-8. [DOI: 10.1053/j.seminoncol.2017.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
631 Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55-66. [PMID: 28361188 DOI: 10.1007/s00259-017-3687-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 14.3] [Reference Citation Analysis]
632 Białkowska J, Kolasińska-Ćwikła A, Mroczkowska D, Sowa M, Grabarczyk Ł, Maksymowicz W, Cichocki A, Ćwikła JB. Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case Report. Pol J Radiol 2017;82:120-5. [PMID: 28344687 DOI: 10.12659/PJR.899007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
633 Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. J Gastrointest Cancer 2016;47:366-74. [PMID: 27619395 DOI: 10.1007/s12029-016-9866-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
634 Popa E, Schnoll-sussman F, Jesudian A, Nandakumar G, Shah MA. Uncommon Cancers of the Stomach. Textbook of Uncommon Cancer 2017. [DOI: 10.1002/9781119196235.ch27] [Reference Citation Analysis]
635 Reidy-lagunes D, Lieu CH, Messersmith WA, Goodman K. Unusual Tumors of the Colon, Rectum, and Anus. Textbook of Uncommon Cancer 2017. [DOI: 10.1002/9781119196235.ch31] [Reference Citation Analysis]
636 Wang L, Matkar S, Xie G, An C, He X, Kong X, Liu X, Hua X. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Cancer Biol Ther 2017;18:229-36. [PMID: 28281917 DOI: 10.1080/15384047.2017.1294291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
637 Tonelli F, Marini F, Giusti F, Brandi ML. Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update. International Journal of Endocrine Oncology 2017;4:43-58. [DOI: 10.2217/ije-2016-0017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
638 Wada H, Matsuda K, Akazawa Y, Yamaguchi Y, Miura S, Ueki N, Kinoshita A, Yoshiura K, Kondo H, Ito M, Nagayasu T, Nakashima M. Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin. Endocr Pathol 2016;27:179-87. [PMID: 27256098 DOI: 10.1007/s12022-016-9436-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
639 Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm083] [Reference Citation Analysis]
640 Luo Y, Chen J, Huang K, Lin Y, Chen M, Xu L, Li ZP, Feng ST. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer 2017;17:154. [PMID: 28231773 DOI: 10.1186/s12885-017-3150-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
641 Panzuto F, Merola E, Pavel ME, Rinke A, Kump P, Partelli S, Rinzivillo M, Rodriguez-Laval V, Pape UF, Lipp R, Gress T, Wiedenmann B, Falconi M, Delle Fave G. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist 2017;22:409-15. [PMID: 28232598 DOI: 10.1634/theoncologist.2016-0351] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
642 Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85. [PMID: 28220021 DOI: 10.1634/theoncologist.2016-0305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
643 Kim ST, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution. Medicine (Baltimore). 2016;95:e3534. [PMID: 27175651 DOI: 10.1097/md.0000000000003534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
644 Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist 2017;22:165-72. [PMID: 28179574 DOI: 10.1634/theoncologist.2016-0175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
645 Nagata K, Tajiri K, Shimada S, Ando T, Hosokawa A, Matsui K, Imura J, Sugiyama T. Rectal Neuroendocrine Tumor G1 with a Solitary Hepatic Metastatic Lesion. Intern Med 2017;56:289-93. [PMID: 28154272 DOI: 10.2169/internalmedicine.56.7523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
646 Kevat D, Chen M, Wyld D, Fagermo N, Lust K. A case of pulmonary carcinoid in pregnancy and review of carcinoid tumours in pregnancy. Obstet Med 2017;10:142-9. [PMID: 29051783 DOI: 10.1177/1753495X16687700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
647 Bournaud C, Kelly A, Hindié E, Tenenbaum F, Faivre-chauvet A, Courbon F, Taïeb D, Dierickx L, Coriat R, Ansquer C. Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice. Médecine Nucléaire 2017;41:42-54. [DOI: 10.1016/j.mednuc.2017.01.001] [Reference Citation Analysis]
648 Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience 2017;11:716. [PMID: 28194228 DOI: 10.3332/ecancer.2017.716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
649 Yalcin S, Bayram F, Erdamar S, Kucuk O, Oruc N, Coker A. Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci 2017;13:271-82. [PMID: 28261279 DOI: 10.5114/aoms.2017.65449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
650 Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol 2017; 23(3): 516-524 [PMID: 28210088 DOI: 10.3748/wjg.v23.i3.516] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
651 Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125-35. [PMID: 28076709 DOI: 10.1056/NEJMoa1607427] [Cited by in Crossref: 1512] [Cited by in F6Publishing: 1620] [Article Influence: 252.0] [Reference Citation Analysis]
652 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
653 Ohmoto A, Rokutan H, Yachida S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci 2017;18:E143. [PMID: 28098761 DOI: 10.3390/ijms18010143] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
654 Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L, Feng S, Zhou Z, Shao C, Chen M, Yu X, Chen J. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13:1165-1174. [PMID: 28454229 DOI: 10.3892/ol.2017.5591] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
655 Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible? Endocr Connect 2017;6:33-8. [PMID: 28069898 DOI: 10.1530/EC-16-0092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
656 Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, Agaimy A, Sipos B, Zamboni G, Weichert W, Esposito I, Pfarr N, Klöppel G. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 2017;30:587-98. [PMID: 28059098 DOI: 10.1038/modpathol.2016.217] [Cited by in Crossref: 127] [Cited by in F6Publishing: 132] [Article Influence: 21.2] [Reference Citation Analysis]
657 Pollard J, O’dorisio MS, O’dorisio T, Menda Y. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors 2017. [DOI: 10.1007/978-3-319-46038-3_20] [Reference Citation Analysis]
658 Kanthan R, Senger J, Ahmed S, Kanthan SC. Pancreatic Neuroendocrine Tumors in the 21<sup>st</sup> Century—An Update. JCT 2017;08:1194-1233. [DOI: 10.4236/jct.2017.813103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
659 Hofman MS. Principles and Application of Molecular Imaging for Personalized Medicine and Guiding Interventions in Neuroendocrine Tumors. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors 2017. [DOI: 10.1007/978-3-319-46038-3_10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
660 Möhlig M, Pape U, Wiedenmann B. Malignome endokriner Organe. Facharztwissen Hämatologie Onkologie 2017. [DOI: 10.1016/b978-3-437-21214-7.00023-7] [Reference Citation Analysis]
661 Sun J. Pancreatic neuroendocrine tumors. Intractable Rare Dis Res 2017;6:21-8. [PMID: 28357177 DOI: 10.5582/irdr.2017.01007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
662 Bergsland EK, Woltering EA, Rindi G, O’dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang Y, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RKS, Klimstra DS. Neuroendocrine Tumors of the Duodenum and Ampulla of Vater. AJCC Cancer Staging Manual 2017. [DOI: 10.1007/978-3-319-40618-3_30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
663 Rorstad OP. Neuroendocrine tumors. Endocrine Biomarkers 2017. [DOI: 10.1016/b978-0-12-803412-5.00009-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
664 Bodei L, Gilardi L, Volterrani D, Paganelli G, Grana CM, Kidd M, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26236-9_50] [Reference Citation Analysis]
665 Rassner M, Lahner H, von Bubnoff N, Lammert F. Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). Geriatrische Onkologie 2017. [DOI: 10.1007/978-3-662-49083-9_30-1] [Reference Citation Analysis]
666 Imperiale A, Deroose CM, Hindié E, Goichot B. Radionuclide Imaging of Gastrointestinal Neuroendocrine Tumors. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors 2017. [DOI: 10.1007/978-3-319-46038-3_15] [Reference Citation Analysis]
667 White RR, Menon VG. Benign and Malignant Tumors of the Liver. Principles and Practice of Geriatric Surgery 2017. [DOI: 10.1007/978-3-319-20317-1_57-1] [Reference Citation Analysis]
668 . References. Molecular Approach to Cancer Management 2017. [DOI: 10.1016/b978-0-12-812896-1.00040-4] [Reference Citation Analysis]
669 Yamada S, Kotake M, Hada M, Kato Y, Oyama K, Hara T. A Case of Neuroendocrine Tumor of the Ileum with Peritoneal Dissemination in which Early Diagnosis was Difficult. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2017;78:64-70. [DOI: 10.3919/jjsa.78.64] [Reference Citation Analysis]
670 Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Ströbel P, May C, Kleylein-Sohn J, Baierlein C, Bogdahn U, Marx A, Schalke B. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS One 2016;11:e0168215. [PMID: 27992479 DOI: 10.1371/journal.pone.0168215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
671 Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 2016;7:5538-47. [PMID: 26701729 DOI: 10.18632/oncotarget.6686] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
672 Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017;6:44-8. [PMID: 28123727 DOI: 10.3892/mco.2016.1097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
673 Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA, Meyer T. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016;115:1540-1547. [PMID: 27875519 DOI: 10.1038/bjc.2016.377] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
674 Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017;9:189-199. [PMID: 28344664 DOI: 10.1177/1758834016678149] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
675 Leung U, Jarnagin WR. Resection of noncolorectal liver metastases. Laparoscopic Liver, Pancreas, and Biliary Surgery 2016. [DOI: 10.1002/9781118781166.ch14] [Reference Citation Analysis]
676 Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer 2016;16:858. [PMID: 27821081 DOI: 10.1186/s12885-016-2901-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
677 Laskaratos FM, Walker M, Naik K, Maragkoudakis E, Oikonomopoulos N, Grant L, Meyer T, Caplin M, Toumpanakis C. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. Br J Cancer. 2016;115:1321-1327. [PMID: 27811856 DOI: 10.1038/bjc.2016.349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
678 Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016;45:1394-400. [PMID: 27171514 DOI: 10.1097/MPA.0000000000000659] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
679 Wadsworth PK, Jones RP, Poston GJ. Resection of primary gastroenteropancreatic neuroendocrine tumors in the presence of irresectable liver metastases. International Journal of Endocrine Oncology 2016;3:291-7. [DOI: 10.2217/ije-2016-0010] [Reference Citation Analysis]
680 Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas 2016;45:1386-93. [PMID: 27622342 DOI: 10.1097/MPA.0000000000000700] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
681 Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
682 Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017;10:132-141. [PMID: 28286565 DOI: 10.1177/1756283x16674660] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
683 Wells SA Jr. Progress in Endocrine Neoplasia. Clin Cancer Res 2016;22:4981-8. [PMID: 27742784 DOI: 10.1158/1078-0432.CCR-16-0384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
684 Söderquist F, Janson ET, Rasmusson AJ, Ali A, Stridsberg M, Cunningham JL. Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours. PLoS One 2016;11:e0164354. [PMID: 27736994 DOI: 10.1371/journal.pone.0164354] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
685 Lee MS, O'Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 2016;7:804-18. [PMID: 27747094 DOI: 10.21037/jgo.2016.08.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
686 Stoelben E, Yordanova A, Gossmann A, Hammer-hellmig M, Brossart P, Mayer K, Essler M. Karzinoide der Lunge. best practice onkologie 2016;11:22-28. [DOI: 10.1007/s11654-016-0586-1] [Reference Citation Analysis]
687 Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino FZ, Patalano R, De Martino MC, Sciammarella C, Faggiano A, Rocco G, Franco R, Kaltsas GA, Colao A, Pivonello R. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine 2017;56:603-20. [PMID: 27688013 DOI: 10.1007/s12020-016-1079-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
688 Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015;34:823-42. [PMID: 26433592 DOI: 10.1007/s10555-015-9598-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
689 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
690 Pavel ME. WOMEN IN CANCER PROFILE: Neuroendocrine tumors: moving from the land of small tumors to an expanding universe. Endocr Relat Cancer 2016;23:P23-6. [PMID: 27645051 DOI: 10.1530/ERC-16-0371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
691 Somnay Y, Lubner S, Gill H, Matsumura JB, Chen H. The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids. Cancer Gene Ther 2016;23:348-54. [PMID: 27632933 DOI: 10.1038/cgt.2016.39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
692 Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, Virgolini I. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14:127. [PMID: 27614762 DOI: 10.1186/s12955-016-0527-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
693 Basuroy R, Srirajaskanthan R, Ramage JK. Neuroendocrine Tumors. Gastroenterol Clin North Am 2016;45:487-507. [PMID: 27546845 DOI: 10.1016/j.gtc.2016.04.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
694 Paul D, Ostwal V, Bose S, Basu S, Gupta S. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective. Eur J Gastroenterol Hepatol 2016;28:985-90. [PMID: 27257869 DOI: 10.1097/MEG.0000000000000674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
695 Gade TP, Soulen MC. Assessment, triage, and liver-directed therapies for neuroendocrine tumor metastases. Interventional Oncology 2016. [DOI: 10.1017/cbo9781107338555.019] [Reference Citation Analysis]
696 Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med 2016;5:2953-64. [PMID: 27539383 DOI: 10.1002/cam4.742] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
697 Kaemmerer D, Träger T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S, Lupp A. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget 2015;6:27566-79. [PMID: 26259237 DOI: 10.18632/oncotarget.4491] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
698 Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534-545. [PMID: 25962092 DOI: 10.4158/ep14464.dsc] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
699 Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. [PMID: 27594907 DOI: 10.3332/ecancer.2016.662] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
700 Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016;115:564-570. [PMID: 27482646 DOI: 10.1038/bjc.2016.229] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
701 Keutgen XM, Babic B, Nilubol N. Management of pancreatic neuroendocrine tumors. International Journal of Endocrine Oncology 2016;3:267-77. [DOI: 10.2217/ije-2016-0002] [Reference Citation Analysis]
702 Merola E, Rinzivillo M, Cicchese N, Capurso G, Panzuto F, Delle Fave G. Digestive neuroendocrine neoplasms: A 2016 overview. Dig Liver Dis 2016;48:829-35. [PMID: 27212431 DOI: 10.1016/j.dld.2016.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
703 Inayat F, Daly KP, Askarian F, Saif MW. Small Bowel Neuroendocrine Tumors with Inguinal Metastases: A Diagnostic and Therapeutic Dilemma. Cureus 2016;8:e692. [PMID: 27555990 DOI: 10.7759/cureus.692] [Reference Citation Analysis]
704 Roviello G, Zanotti L, Venturini S, Bottini A, Generali D. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biol Ther 2016;17:883-8. [PMID: 27414404 DOI: 10.1080/15384047.2016.1210735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
705 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 90] [Cited by in F6Publishing: 98] [Article Influence: 12.9] [Reference Citation Analysis]
706 Yao JC, Voi M, Rouyrre N, Singh S. Everolimus in ileum neuroendocrine tumours – Authors' reply. The Lancet 2016;388:236-237. [DOI: 10.1016/s0140-6736(16)31045-5] [Reference Citation Analysis]
707 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
708 Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One 2016;11:e0158140. [PMID: 27362760 DOI: 10.1371/journal.pone.0158140] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
709 Hope TA, Pampaloni MH, Flavell RR, Nakakura EK, Bergsland EK. Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. Clin Transl Imaging 2017;5:63-9. [DOI: 10.1007/s40336-016-0193-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
710 Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, Leyden J. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol 2017;3:43-53. [PMID: 28717741 DOI: 10.1200/JGO.2015.002980] [Cited by in Crossref: 68] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
711 Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol 2016;13:691-705. [PMID: 27273044 DOI: 10.1038/nrclinonc.2016.85] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
712 Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK. A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist 2016;21:785-6. [PMID: 27261467 DOI: 10.1634/theoncologist.2016-0060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
713 Gut P, Waligórska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Fischbach J, Woliński K, Kaznowski J, Wrotkowska E, Ruchała M. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci 2017;13:515-24. [PMID: 28507564 DOI: 10.5114/aoms.2016.60311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
714 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21:671-675. [PMID: 27226359 DOI: 10.1634/theoncologist.2015-0470] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
715 Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. J Cancer 2016;7:1044-8. [PMID: 27326246 DOI: 10.7150/jca.14815] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
716 Li Y, Simonds WF. Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer 2016;23:R229-47. [PMID: 27207564 DOI: 10.1530/ERC-16-0059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
717 Veenstra MJ, van Koetsveld PM, Dogan F, Farrell WE, Feelders RA, Lamberts SWJ, de Herder WW, Vitale G, Hofland LJ. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget 2018;9:14791-802. [PMID: 29599907 DOI: 10.18632/oncotarget.9462] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
718 Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, Darby C, Wong JL, Davies L, Fletcher S, Shatwell W, Sothi S, Randeva HS, Dimitriadis GK, Weickert MO. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: A cross-sectional study. BMJ Open. 2016;6:e010765. [PMID: 27147385 DOI: 10.1136/bmjopen-2015-010765] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
719 De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med 2016;14:113. [PMID: 27142424 DOI: 10.1186/s12967-016-0857-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
720 Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis 2016;48:552-8. [PMID: 26917486 DOI: 10.1016/j.dld.2015.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
721 Manneh R, Castellano D, Caso O, Loinaz C, Jiménez J, Estenoz J, Calatayud M, Sepúlveda JM, García-Carbonero R. Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case. Case Rep Oncol 2016;9:255-61. [PMID: 27239181 DOI: 10.1159/000445940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
722 Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist 2016;21:701-7. [PMID: 27107003 DOI: 10.1634/theoncologist.2015-0455] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
723 Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N. Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology 2017;104:209-22. [PMID: 27082107 DOI: 10.1159/000446115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
724 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
725 Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer 2016;23:411-8. [PMID: 27080472 DOI: 10.1530/ERC-16-0008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
726 Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine Tumors. Front Oncol. 2016;6:94. [PMID: 27148486 DOI: 10.3389/fonc.2016.00094] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
727 Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
728 Faggiano A, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, Giordano EA, Guarnotta V, Logoluso FA, Messina E, Nicastro V, Nuzzo V, Sciaraffia M, Colao A. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. Oncologist 2016;21:875-86. [PMID: 27053503 DOI: 10.1634/theoncologist.2015-0420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
729 Gregersen T, Brock C, Haase AM, Laurberg S, Drewes AM, Grønbæk H, Krogh K. Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea. J Neurogastroenterol Motil 2016;22:264-71. [PMID: 26690884 DOI: 10.5056/jnm15113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
730 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
731 Luque RM, Villa-Osaba A, L-López F, Pozo-Salas AI, Sánchez-Sánchez R, Ortega-Salas R, de Lecea L, Álvarez-Benito M, López-Miranda J, Gahete MD, Castaño JP. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res 2016;18:29. [PMID: 26956474 DOI: 10.1186/s13058-016-0689-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
732 Anlauf M, Neumann M, Bomberg S, Luczak K, Heikaus S, Gustmann C, Antke C, Ezziddin S, Fottner C, Pavel M, Pape UF, Rinke A, Lahner H, Schott M, Cremer B, Hörsch D, Baum RP, Groh U, Alkatout I, Rudlowski C, Scheler P, Zirbes TK, Hoffmann J, Fehm T, Gabbert HE, Baldus SE. [Neuroendocrine neoplasms of the breast]. Pathologe 2015;36:261-70. [PMID: 25986886 DOI: 10.1007/s00292-015-0024-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
733 Mangano A, Lianos GD, Roukos DH, Mason SE, Kim HY, Dionigi G. New horizons for targeted treatment of neuroendocrine tumors. Future Oncol 2016;12:1059-65. [PMID: 26916705 DOI: 10.2217/fon.16.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
734 Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016;21:308-313. [PMID: 26911407 DOI: 10.1634/theoncologist.2015-0381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
735 Buil-Bruna N, Dehez M, Manon A, Nguyen TX, Trocóniz IF. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors. AAPS J 2016;18:703-12. [PMID: 26908127 DOI: 10.1208/s12248-016-9884-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
736 Godard-Sebillotte C, Dramé M, Fagour C, Basileu T, Godaert L. When Symptomatic Treatment Becomes Antitumor Treatment for Vipoma: Opportunity for Frail Elderly Adults. J Am Geriatr Soc 2016;64:449-50. [PMID: 26889855 DOI: 10.1111/jgs.13968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
737 Detweiler CJ, Cardona DM, Hsu DS, McCall SJ. Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis. BMJ Case Rep. 2016;2016. [PMID: 26884076 DOI: 10.1136/bcr-2015-214206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
738 Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, van Echteld CJ. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics 2016;6:501-10. [PMID: 26941843 DOI: 10.7150/thno.13702] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
739 Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D, Alexandrakis G, Papakostas P, Vaslamatzis M, Kaldrymidis P, Markussis V, Koumarianou A; “G-NET-Registry” investigators. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord 2016;16:8. [PMID: 26872616 DOI: 10.1186/s12902-016-0089-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
740 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
741 Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther 2016;9:699-704. [PMID: 26929640 DOI: 10.2147/OTT.S72155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
742 Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E, Gryczyńska M, Ruchała M. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 2016;12:1-9. [PMID: 26925113 DOI: 10.5114/aoms.2016.57577] [Cited by in Crossref: 60] [Cited by in F6Publishing: 74] [Article Influence: 8.6] [Reference Citation Analysis]
743 Keizer AC, Korse TC, Meijer WG, Tesselaar ME. The effect of delay in diagnosis in patients with neuroendocrine tumors. International Journal of Endocrine Oncology 2016;3:33-9. [DOI: 10.2217/ije.15.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
744 Mohammadi H, Chuong MD, Moeslein FM, Sharma NK. Selective internal radiation therapy for the treatment of inoperable neuroendocrine tumor liver metastases. International Journal of Endocrine Oncology 2016;3:77-83. [DOI: 10.2217/ije.15.33] [Reference Citation Analysis]
745 Rayado GG, Marco MS. Tumores del intestino delgado. Pólipos intestinales. Poliposis familiares. Síndrome carcinoide. Linfomas. Sarcomas intestinales. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:189-196. [DOI: 10.1016/j.med.2016.02.012] [Reference Citation Analysis]
746 Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016;57:708-714. [PMID: 26769865 DOI: 10.2967/jnumed.115.163865] [Cited by in Crossref: 132] [Cited by in F6Publishing: 142] [Article Influence: 18.9] [Reference Citation Analysis]
747 Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 2016;12:313-21. [PMID: 26759064 DOI: 10.2217/fon.15.321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
748 Younan G, Tsai S, Evans DB, Christians KK. Neuroendocrine Tumors of the Pancreas. Pancreas and Biliary Disease 2016. [DOI: 10.1007/978-3-319-28089-9_7] [Reference Citation Analysis]
749 Clift AK, Faiz O, Al-Nahhas A, Bockisch A, Liedke MO, Schloericke E, Wasan H, Martin J, Ziprin P, Moorthy K, Frilling A. Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours. J Gastrointest Surg 2016;20:180-8; discussion 188. [PMID: 26394880 DOI: 10.1007/s11605-015-2953-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
750 Maron DJ. Carcinoids, GISTs, and Lymphomas of Colon and Rectum. The ASCRS Textbook of Colon and Rectal Surgery 2016. [DOI: 10.1007/978-3-319-25970-3_38] [Reference Citation Analysis]
751 Ladd AP, Grosfeld JL. Gastrointestinal Tumors in Children. The Surgery of Childhood Tumors 2016. [DOI: 10.1007/978-3-662-48590-3_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
752 Hendifar AE, Liu S, Wolin E. The Role of mTOR Inhibitors in Neuroendocrine Tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future 2016. [DOI: 10.1007/978-2-8178-0492-7_5] [Reference Citation Analysis]
753 Zeuß D, Marth T. Tumoren des Dünndarms. DGIM Innere Medizin 2016. [DOI: 10.1007/978-3-642-54676-1_336-2] [Reference Citation Analysis]
754 Cho JH. Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors. Korean J Gastroenterol 2016;68:169. [DOI: 10.4166/kjg.2016.68.3.169] [Reference Citation Analysis]
755 Kondo S. Molecular-targeted Therapies in Gastrointestinal Cancer. J Jpn Soc Intern Med 2016;105:1051-1060. [DOI: 10.2169/naika.105.1051] [Reference Citation Analysis]
756 Magliocco AM. Molecular Pathology of Neuroendocrine Tumor: The Era of Targeted Therapeutics. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_23] [Reference Citation Analysis]
757 Fazio N, Spada F. Management of Neuroendocrine Tumors. PET/CT in Neuroendocrine Tumors 2016. [DOI: 10.1007/978-3-319-29203-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
758 Minami T, Nishihira T, Miki A, Suzuki T, Otani T, Kitamura K, Ogino T. Efficacy of Octreotide as Adjuvant Therapy for Rectal Advanced Neuroendocrine Carcinoma—A Case Report—. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2016;77:1192-1196. [DOI: 10.3919/jjsa.77.1192] [Reference Citation Analysis]
759 Sliesoraitis S, George TJ. Chemotherapy. Pancreatic Masses 2016. [DOI: 10.1007/978-3-319-19677-0_19] [Reference Citation Analysis]
760 Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, Caplin ME, Meyer T. Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clin Cancer Res 2016;22:79-85. [PMID: 26199388 DOI: 10.1158/1078-0432.CCR-15-1008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
761 Henderson-jackson E, Sheikh U, Muhammad J, Coppola D, Nasir A. Neuroendocrine Neoplasms of the Stomach. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_12] [Reference Citation Analysis]
762 Begum N. Chirurgie von neuroendokrinen Neoplasien bei alten Patienten. Onkologische Chirurgie bei alten Patienten 2016. [DOI: 10.1007/978-3-662-48712-9_20] [Reference Citation Analysis]
763 Kwon JH. Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma. Korean J Med 2016;90:7-14. [DOI: 10.3904/kjm.2016.90.1.7] [Reference Citation Analysis]
764 Öberg K. Carcinoid Syndrome. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00151-7] [Reference Citation Analysis]
765 Soares HP, Strosberg J. Targeted Therapies for Neuroendocrine Neoplasms. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_28] [Reference Citation Analysis]
766 Hameed U, Cukier M, Hallet J, Law CHL, Rowsell C, Singh S. Neuroendocrine Tumors (GastroEnteroPancreatic). Surgical Oncology Manual 2016. [DOI: 10.1007/978-3-319-26276-5_16] [Reference Citation Analysis]
767 Bodei L, Gilardi L, Volterrani D, Paganelli G, Grana CM, Kidd M, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2016. [DOI: 10.1007/978-3-319-26067-9_50-1] [Reference Citation Analysis]
768 Komatsubara T, Koinuma K, Miyakura Y, Horie H, Morimoto M, Ito H, Lefor AK, Sata N, Fukushima N. Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation. Clin J Gastroenterol. 2016;9:1-6. [PMID: 26699873 DOI: 10.1007/s12328-015-0623-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
769 Kos-Kudła B. Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemp Oncol (Pozn) 2015;19:345-9. [PMID: 26793016 DOI: 10.5114/wo.2015.56006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
770 Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours; Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968-977. [PMID: 26703889 DOI: 10.1016/s0140-6736(15)00817-x] [Cited by in Crossref: 687] [Cited by in F6Publishing: 758] [Article Influence: 85.9] [Reference Citation Analysis]
771 Yarmohammadi H, Erinjeri JP, Brown KT. Embolization of metastatic neuroendocrine tumor resulting in clinical manifestations of syndrome of inappropriate secretion of antidiuretic hormone. J Vasc Interv Radiol 2015;26:533-7. [PMID: 25805538 DOI: 10.1016/j.jvir.2014.11.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
772 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015;19:2273-82. [PMID: 26341823 DOI: 10.1007/s11605-015-2931-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
773 Gurung B, Hua X, Runske M, Bennett B, LiVolsi V, Roses R, Fraker DA, Metz DC. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target. Cancer Biol Ther. 2015;16:219-224. [PMID: 25482929 DOI: 10.4161/15384047.2014.987574] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
774 Jensen RT. Zollinger–Ellison Syndrome. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
775 Carolan PJ, Chung DC. Neuroendocrine Tumors of the Pancreas. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch88] [Reference Citation Analysis]
776 Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol 2016;51:513-23. [PMID: 26605828 DOI: 10.3109/00365521.2015.1115117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
777 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
778 Maxwell JE, O'Dorisio TM, Howe JR. Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2016;25:171-94. [PMID: 26610781 DOI: 10.1016/j.soc.2015.08.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
779 Lansdown A, Rees A. Management of neuroendocrine tumours. Practical Clinical Oncology 2015. [DOI: 10.1017/cbo9781107280250.041] [Reference Citation Analysis]
780 Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:119-133. [PMID: 26614372 DOI: 10.1016/j.hoc.2015.09.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
781 Paniccia A, Edil BH, Schulick RD. Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg 2015;77:395-402. [PMID: 26722203 DOI: 10.1007/s12262-015-1360-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
782 Ouyang B, Ma X, Yan H, He J, Xia C, Yu H. Renal carcinoid tumor with liver metastasis followed up postoperatively for 9 years. Diagn Pathol 2015;10:182. [PMID: 26445413 DOI: 10.1186/s13000-015-0417-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
783 Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. Aliment Pharmacol Ther 2015;42:1033-4. [PMID: 26374262 DOI: 10.1111/apt.13381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
784 Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9:1407-1419. [PMID: 26413978 DOI: 10.1586/17474124.2015.1092383] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
785 Maxwell JE, Sherman SK, Li G, Choi AB, Bellizzi AM, O'Dorisio TM, Howe JR. Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genet 2015:S2210-7762(15)00184-2. [PMID: 26603463 DOI: 10.1016/j.cancergen.2015.08.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
786 Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer 2015;22:933-40. [PMID: 26373569 DOI: 10.1530/ERC-15-0314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
787 Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-5086. [PMID: 26366058 DOI: 10.2147/dddt.s84177] [Cited by in Crossref: 133] [Cited by in F6Publishing: 141] [Article Influence: 16.6] [Reference Citation Analysis]
788 Noe S, Neu B. Gastroenteropankreatische neuroendokrine Neoplasien (GEP-NEN). Gastroenterologe 2015;10:418-421. [DOI: 10.1007/s11377-015-0013-0] [Reference Citation Analysis]
789 Pape U, Maasberg S, Pschowski R, Wiedenmann B. Neue medikamentöse Therapien bei neuroendokrinen Neoplasien. Gastroenterologe 2015;10:422-428. [DOI: 10.1007/s11377-015-0005-0] [Reference Citation Analysis]
790 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
791 Wolin EM. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist 2015;20:1123-31. [PMID: 26306904 DOI: 10.1634/theoncologist.2015-0198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
792 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
793 Bainbridge HE, Larbi E, Middleton G. Symptomatic Control of Neuroendocrine Tumours with Everolimus. Horm Cancer. 2015;6:254-259. [PMID: 26245686 DOI: 10.1007/s12672-015-0233-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
794 Shenoy S. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies. J Gastrointest Cancer. 2014;45:421-430. [PMID: 25339426 DOI: 10.1007/s12029-014-9658-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
795 Wada R, Yagihashi S. The expression of glucagon-like peptide-1 receptor and dipeptidyl peptidase-IV in neuroendocrine neoplasms of the pancreas and gastrointestinal tract. Endocr Pathol 2014;25:390-6. [PMID: 25119061 DOI: 10.1007/s12022-014-9326-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
796 Tabaksblat EM, Langer SW, Knigge U, Grønbæk H, Mortensen J, Petersen RH, Federspiel BH, Ladekarl M. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. Acta Oncol 2016;55:3-14. [PMID: 26223571 DOI: 10.3109/0284186X.2015.1067715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
797 Norton JA, Krampitz G, Jensen RT. Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am 2015;24:795-832. [PMID: 26363542 DOI: 10.1016/j.soc.2015.06.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
798 Rey Vázquez SM, Marcos Vidal JM, Echevarría Blasco N, González de Gastro R. [Carcinoid heart disease. Role of octreotide in perioperative management]. Rev Esp Anestesiol Reanim 2016;63:122-3. [PMID: 26188976 DOI: 10.1016/j.redar.2015.06.005] [Reference Citation Analysis]
799 Alonso-Gordoa T, Díez JJ, Molina J, Reguera P, Martínez-Sáez O, Grande E. An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers Ther 2015;3:13-33. [PMID: 27182476 DOI: 10.1007/s40487-015-0007-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
800 Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer 2015;15:495. [PMID: 26138480 DOI: 10.1186/s12885-015-1512-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
801 Rao VL, Micic D, Rubin DT. Hematochezia and a Mesenteric Mass. Gastroenterology 2015;149:e12-3. [PMID: 26026749 DOI: 10.1053/j.gastro.2014.12.039] [Reference Citation Analysis]
802 Chihaya K, Morita S, Sone M, Kishi Y, Okusaka T, Arai Y. Strategy for treatment of a nonfunctioning pancreatic neuroendocrine neoplasm with liver metastases. Int Canc Conf J 2015;4:133-137. [DOI: 10.1007/s13691-015-0226-6] [